9&7 -RKQVRQ 	 -RKQVRQ 9LVLRQ &DUH ,QF
Clinical Study Protocol
Evaluation of the JJVC Investig ational Toric Multifocal 
Contact [CONTACT_615557]
3URWRFRO &5
9HUVLRQ 2.0, Amendment 1
'DWH  14-Mar-2017 
Investigational Products: JJVC I nvestigational etafilcon A Tori c Multifocal Contact [CONTACT_391346] 
1-Day AcuvueÂ® Moist Brand Multifocal Contact [CONTACT_615558]: Multifocal, Astigma tism, etafilcon A, Non-Dispensing , Daily-wear, Presby[CONTACT_19555] 
6WDWHPHQW RI &RPSOLDQFH WR SURWR FRO *&3DQG DSSOLFDEOH UHJXODW RU\ JXLGHOLQHV
This trial will be conducted in compliance with the protocol, the International Conference on 
Harmonization Good Clinical Pra ctice E6 (ICH-GCP), ISO [ZIP_CODE], t he Declaration of 
Helsinki, and all applicable  regulatory requirements.
&RQILGHQWLDOLW\6WDWHPHQW
This document contains confidential information, which should n ot be copi[INVESTIGATOR_530], referred to, 
released or published without w ritten approval from [COMPANY_012] Vision Care, Inc.
The information may not be disclosed to others except to the extent necessary to obtain 
Institutional Review Board/Independent Ethics Committee approva l and informed consent, or 
as required by [CONTACT_19543], Federal and State Laws, as applic able. Persons to whom this 
information is disclosed must be informed that this information  is privileged and confidential 
and that it should not be furthe r disclosed without the written  permission of Johnson & 
Johnson Vision Care, Inc.  Any supplemental information that ma y be added to this 
document is also confidential and proprietary to Johnson & John son Vision Care, Inc. and 
must be kept in confidence in the s ame manner as the contents o f this document. 
CR-5913 v2.0, Amendment 1.0 Page 1 of 183 JJVC CONFIDENTIAL
9&7 7$%/( 2)&217(176
PROTOCOL TITLE, NUMBER, VERSION ......................................................................6  
SPONSOR NAME [CONTACT_71191] ...................................... ............................................6  
MEDICAL MONITOR ............................................... .........................................................6  
AUTHORIZED SIGNATURES ..........................................................................................7  
CHANGE HISTORY................................................. ..........................................................8  
SYNOPSIS ...........................................................................................................................9  
Figure 1: Study Flowchart ..................................... .........................................................[ADDRESS_816232] Article  Allocation .........................................................................................21  
5.2. Masking ................................................................................................................21  
CR-5913 v2.0, Amendment 1.0 Page 2 of 183 JJVC CONFIDENTIAL
9&7 5.3. Procedures for Maintaining a nd Breaking Randomization Codes ... ....................[ADDRESS_816233] Articles ..................................... ...................................................21  
Table 1: Test Articles ........................................ ..............................................................21  
6.2. Ancillary Supplies/Products ................................... ..............................................23  
Table 2: Ancilla ry Supplies ............................................................................................[ADDRESS_816234] Articles ............................... .............................................24  
7. STUDY EVALUATIONS ...........................................................................................25  
7.1. Time and Event Schedule ....................................... ..............................................25  
Table 3: Time and Events ...................................... .........................................................25  
7.2. Detailed Study Procedures ..................................... ..............................................26  
VISIT 1 ...................................................................................................................... 26  
FINAL EVALUATION .............................................. .............................................. 30  
7.3. Unscheduled Visits ............................................ ...................................................30  
7.4. Laboratory Procedures ......................................... ................................................32  
8. SUBJECTS COMPLETION/WITHDRAWAL................................. ..........................32  
8.1. Completion Criteria ..............................................................................................32  
8.2. Withdrawal/Discontinuation from the Study .......................................................32  
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ............. .[ADDRESS_816235] QUALITY COMPLAINTS ............. .34 
13. ADVERSE EVENTS ................................................ ...................................................35  
13.1.  Definitions and Classifications .............................................................................35  
13.2.  Assessing Adverse Events ....................................................................................38  
13.2.1  Causality Assessment .................................................................................... 38  
13.2.2  Severity Assessment ...................................................................................... 38  
13.3.  Documentation and Follow-Up of Adverse Events .............................................39  
CR-5913 v2.0, Amendment 1.0 Page 3 of 183 JJVC CONFIDENTIAL
9&7 13.4.  Reporting Adverse Events ...................................... ..............................................40  
13.4.1  Reporting Adverse Events to Sponsor ........................................................... 40  
13.4.2  Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities
 [ADDRESS_816236] KEEPI[INVESTIGATOR_1645]/ARCHIVING .................... ............45  
15.1.  Electronic Case Report Form/Data Collection ................... ..................................[ADDRESS_816237] ................................................ .....................................................45  
16. DATA MANAGEMENT................................................ .............................................46  
16.1.  Access to Source Data/Document ................................ ........................................[ADDRESS_816238] (IEC /IRB) ..........[ADDRESS_816239] RETENTION......................................... .......................................50  
CR-5913 v2.0, Amendment 1.0 Page 4 of 183 JJVC CONFIDENTIAL
9&7 20. FINANCIAL CONSIDERATIONS ...................................... ......................................51  
21. PUBLICATION ...........................................................................................................51  
REFERENCES .................................................... ..............................................................51  
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) 52  
APPENDIX B: PATIENT INSTRUCTION GUIDE ......................... ...............................58  
APPENDIX C: PACKAGE INS ERT (APPROVED PRODUCT) ....................................59  
APPENDIX D: CLINICAL TECHNICAL PROCEDURES (CTP) ............... ..................88  
APPENDIX E: PRESBY[CONTACT_539441] ............................... ....................................89  
APPENDIX F: OCULAR DOMINANCE................................... ......................................90  
APPENDIX G: FITTING GUIDE OPTION 1 ............................ ......................................91  
APPENDIX H: FITTING GUIDE OPTION 2 ............................ ......................................96  
APPENDIX I: SUBJECT PRODUCT CONCEPT............................ ..............................103  
APPENDIX J: ECP INTERVIEW DISCUSSION materials ................ ..........................105  
CTP-2002: LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS .............................131  
CTP-2003: EXPANDED SODIUM FLUOR ESCEIN CORNEAL STAINING.............139  
CTP-2005: DETERMINATION OF NEAR ADD ........................... ...............................144  
CTP-2008: LENS FITTING CHARACTERISTICS ........................ ...............................152  
CTP-2009: SUBJECT REPORTED OCULAR SYMPTOMS ........................................159  
CTP-2016: DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS ................................................... ...........................................................161  
CTP-2018: BIOMICROSCOPY SCALE ........................................................................168  
CTP-2025: DISTANCE AND NEAR VISUAL ACUITY EVALUATION .......... .........174  
CTP-2027: TORIC FIT EVALUATION ................................ .........................................179  
/,67,1*2)7$%/(6
Table 1: Test Articles ........................................ .................................................................21  
Table 2: Ancilla ry Supplies ...............................................................................................23  
Table 3: Time and Events ...................................... ............................................................25  
/,67,1*2)),*85(6
Figure 1: Study Flowchart ...................................................................................................... 13  
CR-5913 v2.0, Amendment 1.0 Page 5 of 183 JJVC CONFIDENTIAL
9&7 [ZIP_CODE]&2/ 7,7/(180%(5 9(56,21
Title: Evaluation of the JJVC Inv estigational Toric Multifocal C ontact Lens Fitting Guide
Protocol Number: CR-5913 
Version: 2.0, Amendment 1 Date: 14-Mar-2017 
63216251$0( $1'$''5(66
[COMPANY_012] Vision Care, Inc. (JJVC) 
[ADDRESS_816240],  Jacksonville, FL [ZIP_CODE] 
0(',&$/ 021,725
Name: [CONTACT_19617] R. Karkkainen, OD, MS, FAAO
Title: Sr. Principal Research Optometrist
Address: [ADDRESS_816241] Telephone: ([PHONE_12726] Email: [EMAIL_336]
The Medical Monitor must be notified by [CONTACT_19545] n/site by e-mail, fax, or 
telephone within 24 hours of learning  of a Serious Adverse Event .   T h e  M e d i c a l  M o n i t o r  
may be contact[CONTACT_615559].  General study related 
questions should be directed towards your assigned clinical res earch associate. 
The Medical Monitoring Plan is maintained as a separate document and included in the Trial Master File.
CR-5913 v2.0, Amendment 1.0 Page 6 of 183 JJVC CONFIDENTIAL
9&7 $87+25,=('6,*1$785([ADDRESS_816242] Manager-Data and SystemsDATE
Approver
Khaled ChehabPresby[CONTACT_539443]. ManagerDATE
CR-5913 v2.0, Amendment 1.0 Page 7 of 183 JJVC CONFIDENTIAL
9&7 6<1236,[ADDRESS_816243] Article(s) Inves tigational Products: eta filcon A Toric Multif ocal Contact 
[CONTACT_615560]:1-Day AcuvueÂ® Moist Brand Multifocal 
Contact [CONTACT_615561]: Daily WearReplacement Schedule: None- Non-dispensing study 
Objectives The primary objective of  this study is an evaluation  of the 
JJVC Investigational Toric Multifocal and 1-Day AcuvueÂ® 
Moist Brand Multifocal Contact [CONTACT_615562] (ECPs).
Study Endpoints Primary endpoint : The maximum number of lens 
modifications for both eyes required by [CONTACT_615563].     Secondary endpoint:  
1. Subjective feedback from the ECP on the fitting guide 
process (i.e. intuitive nature of the fitting steps, 
adequate amount of informa tion provided by [CONTACT_615564], strengths and weaknesses, etc.) 
2. Subjective feedback from the ECP regarding the layout 
of the fitting guide.
3. Surveys of the subjects experience.
CR-5913 v2.0, Amendment 1.0 Page 9 of 183 JJVC CONFIDENTIAL
9&7 Study Design This study is a single arm, non-randomized, open la bel, non-
dispensing clinical trial. The key assessments for this study 
will be the number of  fitting modifications and ECP feedback 
throughout the fit process while using the Fit Guide. Each ECP will fit at least [ADDRESS_816244] satisfy all of the following criteria to 
be enrolled in the study:1. The subject must read, understand, and sign theSTATEMENT OF INFORMED CONSENT and receive a    fully executed copy of the form.2. The subject must appear able and willing to adhere to the 
instructions set forth in this clinical protocol.3. Healthy adult males or femal es that are at least [ADDRESS_816245] 
lens correction (e.g., reading spectacles over contact [CONTACT_13276], 
multifocal or monovision contact [CONTACT_615565], etc.) or if not respon d 
positively to at least one symptom on the â€œPresby[CONTACT_391351]â€.   5. The subject is a current soft spherical or toric contact [CONTACT_615566] (defined as a minimum  of [ADDRESS_816246] two days of the week for  a minimum of 1 month prior to 
the study). 6. The subjectâ€™s distance sphe rical equivalent or spherical 
component (if fit with toric lens) of their refraction must be i n 
the range -1.[ADDRESS_816247]â€™s refractive cylinder must be 0.00D to -1.[ADDRESS_816248]â€™s refractive cyli nder axis must be 90Â°Â±30Â° or 
180Â°Â±30Â° in each eye. 9. The subjectâ€™s ADD power mu st be in the range of +0.75 D
CR-5913 v2.0, Amendment 1.0 Page 10 of 183 JJVC CONFIDENTIAL
9&7 to +2.[ADDRESS_816249] c orrected visual acuity of 
20/20-[ADDRESS_816250] a wea rable pair of spectacles if 
required for their distance vision. 
Potential subjects who meet any of  the following criteria will 
be excluded from particip ating in the study:  
1. Ocular or systemic a llergies or disease , or use of medication 
which might interfere w ith contact [CONTACT_13279].
2. Pregnancy or lactation.
3. Currently diagnosed with diabetes.  4. Infectious diseases (e.g . hepatitis, tuberculosis) or an 
immune-suppressive disease (e.g. HIV). 5. Clinically significant (Grade 3 or 4) corneal edema, corneal vascularization, corne al staining, tarsal abnormalities or bulb ar 
injection, or any other corneal or  ocular abnormalities which 
would contraindicate contact [CONTACT_13279].
6. Entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], extrusions, chalazia, recurrent styes,  
dry eye, glaucoma, history of  recurrent corneal erosions.
7. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, lid procedures, cataract surgery, retinal surgery, etc.). 8. A history of amblyopia, strabismus or binocular vision abnormality. 9. Any ocular infection or inflammation.10. Any ocular abnormality that may interfere with contact 
[CONTACT_13279].  11. Use of any ocular medica tion, with the exception of 
rewetting drops. 12. History of herpetic keratitis.13. Participation in any contact l ens or lens care product 
clinical trial within 30 days pr ior to study enrollment.
14. Employee of clinical site (e.g., Investigator, Coordinator, Technician)
Disallowed Medications/Interventions  Any systemic medications that may affect contact [CONTACT_615567].    
CR-5913 v2.0, Amendment 1.0 Page 11 of 183 JJVC CONFIDENTIAL
9&7 Measurements and 
ProceduresThe key assessments for this study will be the number of 
fitting modifications and ECP feedback throughout the fit process while using the Fit Guide. 
Microbiology or Other Laboratory TestingNone
Study Termination The occurrence  of one or more Unanticipated Ad verse Device 
Effect (UADE), or any SAE where  relationship to study agent 
cannot be ruled out, will result in s toppi[INVESTIGATOR_615546].  In the  event of a UADE or SAE, the 
Sponsor Medical Monitor may  unmask the treatment regimen 
of subject(s) and may discuss this with the Principal 
Investigator [INVESTIGATOR_35435].
Ancillary Supplies/ Study-Specific MaterialsEye-Cept
Â®rewetting drops
Principal Investigator(s) and Study Institution(s)/Site(s)A full list of Principal Investigators, clinical sites, and institutions is kept separately from the Study Protocol and is 
included in the study Trial Master File.
CR-5913 v2.0, Amendment 1.0 Page 12 of 183 JJVC CONFIDENTIAL
9&7 Figure 1: Study Flowchart
CR-5913 v2.0, Amendment 1.0 Page 13 of 183 JJVC CONFIDENTIAL
9&7 &[ZIP_CODE]/<86('$%%5(9,$7,216 $1''(),1,7,216 2)7(506
ADD   Plus Power Required For Near Use 
ADE   Adverse Device EffectAE   Adverse Event/Adverse ExperienceBCVA   Best Corrected Visual AcuityBSCVA  Best Spectacle Corrected Visual AcuityCFR   Code of Federal RegulationsCLUE   Contact [CONTACT_615568]â€™s BrochureICF   Informed Consent FormICH   International Conference on Harmonization IDE   Investigational Device ExemptionIEC   Independent Ethics Committee IRB   Institutional Review BoardISO   International Organi zation for Standardization 
ITT   Intent-to-TreatJJVC   [COMPANY_012] Vision Care, Inc. LC   Limbus Center LogMAR  Logarithm of Minimal Angle of ResolutionMedDRA
Â©  Medical Dictionary for Regulatory Activities
MOP   Manual of Procedures NIH   National Institutes of HealthOD   Right EyeOHRP   Office for Human R esearch Protections 
OHSR   Office for Human Subjects ResearchO S    L e f t  E y eOU   Both EyesPD   Protocol Deviation 
CR-5913 v2.0, Amendment 1.0 Page 14 of 183 JJVC CONFIDENTIAL
9&7 PHI   Protected Health Information
PI   [INVESTIGATOR_615547]/S erious Adverse Experience
SAP   Statistical Analysis PlanSAS   Statistical Analysis SystemSD   Standard Deviation SOP   Standard Ope rating Procedure 
UADE   Unanticipated Adverse Device Effect[LOCATION_003]DE  Unanticipated Serious Adverse Device EffectVA   Visual Acuity
CR-5913 v2.0, Amendment 1.0 Page 15 of 183 JJVC CONFIDENTIAL
9&7 Secondary Objective(s)  
1. Subjective feedback from the ECP on the fitting guide process  (i.e. intuitive nature of 
the fitting steps, adequate amount  of information provided by t he fitting guide, 
strengths and w eaknesses, etc.)
2. Subjective feedback from the EC P regarding the layout of the fitting guide. 
3. Surveys of the subjects experience.
Exploratory Objective(s) Not Applicable 
 (QGSRLQWV
The endpoints will be the numbe r of lenses required for optimiz ation of vision (i.e. ease of 
fit) and subjective responses from the ECPs regarding the mater ials/process used for fitting 
the lenses as well as subjective responses from the subjects. 
Primary Endpoint(s) 
Number of lenses required to optimize vision. 
Secondary Endpoint(s)  
1. Subjective feedback from the ECP on the fitting guide process  (i.e. intuitive nature of 
the fitting steps, adequate amount  of information provided by t he fitting guide, 
strengths and wea knesses, etc.) 
2. Subjective feedback from the EC P regarding the layout of the fitting guide.
3. Surveys of the subjects experience.
Other Observation(s)  
 +\SRWKHVHV
Primary Hypotheses
The maximum number of modification required by [CONTACT_615569] 50% of the subjects.   
Secondary Hypotheses
Not Applicable 
Other Hypotheses 
Not applicable
 7$5*(7('678'< 3238/$7,21
 *HQHUDO&KDUDFWHULVWLFV
Healthy male and female volunteers who are presby[CONTACT_615570] r ecruited for the study. The 
subjects will all be adapted wearers of soft contact [CONTACT_66225]. 
CR-5913 v2.0, Amendment 1.0 Page 18 of 183 JJVC CONFIDENTIAL
9&7  ,QFOXVLRQ &ULWHULD
Potential subjects must satisfy all of the following criteria t o be enrolled in the study:
1. The subject must read, understand, and sign the STATEMENT OF INFORMED 
CONSENT and receive a fully executed copy of the form 
2. The subject must appear able and willing to adhere to the ins tructions set forth in this 
clinical protocol.
3. Healthy adult males or females  that are at least [ADDRESS_816251] lens correction (e.g., reading 
spectacles over contact [CONTACT_13276] , multifocal or monovision contac t lenses, etc.) or if not 
respond positively to at least one symptom on the â€œPresby[CONTACT_463374] S ymptoms 
Questionnaireâ€.   
5. The subject is a current soft spherical or toric contact [CONTACT_35560] (defined as a 
minimum of [ADDRESS_816252] two days of the wee k for a minimum of 
1 month prior to the study). 
6. The subjectâ€™s distance spheri cal equivalent or spherical comp onent (if fit with a toric 
lens) of their refraction must  be in the range -1.[ADDRESS_816253]â€™s refractive cylinder must be 0.[ADDRESS_816254]â€™s refractive cy linder axis must be 90Â°Â±30Â° or 180Â°Â±30Â° in each eye. 
9. The subjectâ€™s ADD power must be in the range of +0.75 D to +[ADDRESS_816255] c orrected visual acuity of 20/20-[ADDRESS_816256] a wearab le pair of spectacles if requi red for their distance 
vision. 
 ([FOXVLRQ &ULWHULD
Potential subjects who meet any of the following criteria will be excluded from participating 
in the study: 
1. Ocular or systemic a llergies or disease, o r use of medication which might interfere 
with contact [CONTACT_13279].
2. Pregnancy or lactation.3. Currently diagnosed with diabetes.  4. Infectious diseases (e.g. hepatitis, tuberculosis) or an immu ne-suppressive disease 
(e.g. HIV).
5. Clinically significant (Grad e 3 or 4) corneal edema, corneal vascularization, corneal 
staining, tarsal abnor malities or bulbar injection, or any othe r corneal or ocular 
abnormalities which wou ld contraindicate c ontact lens wear.
6. Entropi[INVESTIGATOR_2394], ectropi[INVESTIGATOR_2394], extrusions, c halazia, recurrent styes, dry eye, glaucoma, history 
of recurrent corneal erosions. 
7. Any previous, or planned, ocular or intraocular surgery (e.g., radial keratotomy, PRK, 
LASIK, lid procedures, cataract surgery, retinal surgery, etc.) .
8. A history of amblyopia, str abismus or binocular vision abnormality. 
CR-5913 v2.0, Amendment 1.0 Page 19 of 183 JJVC CONFIDENTIAL
9&7 9. Any ocular infection or inflammation.
10. Any ocular abnormality that m ay interfere with contact [CONTACT_13279].  
11. Use of any ocular medicati on, with the exception of rewettin g drops. 
12. History of herpetic keratitis.13. Participation in any contact [CONTACT_171185] 30 days prior 
to study enrollment.
14. Employee of clinical site (e.g ., Investigator, Coordinator, Technician) 
 (QUROOPHQW 6WUDWHJ\
Study subjects will be recruited from the potentially eligible subjects identified in the clinical 
siteâ€™s subject database.   
 678'< '(6,*1 $1' 5$7,21$/(
 'HVFULSWLRQ RI 6WXG\ 'HVLJQ
This study is a single arm, non-randomized, open label, bilateral, non-dispensing clinical trial. There is one study visit.  Each subject will wear lenses for approximately 30-[ADDRESS_816257] to use outside of th is clinical trial.
 6WXG\ 'HVLJQ5DWLRQDOH
The primary aim of the study is to obtain ECP feedback on the f itting process of the lenses.  
With this aim in mind, the study design attempts to create the typi[INVESTIGATOR_615548]. The primary purpose of the study is to obtain feedback on the ease of fitting and fitting guide for  the multifocal toric lenses and 
as such there is no need for a Control lens or masking of any of the study personnel.  
 (QUROOPHQW 7DUJHW DQG6WXG\ 'XUDWLRQ
xApproximately [ADDRESS_816258].  Each ECP 
will fit a minimum of 3 subjects and a maximum of 4.   
CR-5913 v2.0, Amendment 1.0 Page 20 of 183 JJVC CONFIDENTIAL
9&7 
 6WRUDJH &RQGLWLRQV
Test articles will be maintained at ambient temperatures at the  clinical site. Test articles must 
be kept under secure conditions. 
 &ROOHFWLRQDQG6WRUDJH RI 6DPSOHV
Test articles will be disposed of after use and not collected u nless associated with an Adverse 
Event.  When possible, any lens or Test article associated with a n Adverse Events and/or a 
Product Quality Complaint must b e retained and stored in a glass vial with moderate solution 
pending directions from the s ponsor for potential return back t o JJVC. 
 $FFRXQWDELOLW\ RI 7HVW $UWLFOHV
JJVC will provide the Investigator with sufficient quantities of  study articles and supplies to 
complete the investigation.  The Investigator is asked to retai n all lens shipment 
documentation for the Test ar ticle accountability records.  
Test article must be kept in a locked storage cabinet, accessibl e only to those assigned by [CONTACT_35500]. The Investigator may delegate this  activity to authorized study 
site personnel listed on the Site  Delegation Log. All Test artic les must be accounted.  This 
includes: 
1. What was dispensed for the subject for trial fitting, to wear  out of the office, or issued 
for the subject to replace appropriately between visits 
2. What was returned to the Investigator unused 
3. The number and reason fo r unplanned replacements.   
The Investigator will collect all unused Test articles from the  subjects at the end of the 
subjectâ€™s participation. Subject r eturned unused Test articles m ust be separated from the 
clinical study inventory of un-dispensed Test articles, and mus t be labeled with the subject 
number and date of return.  Following final reconciliation of T est articles by [CONTACT_2037], the 
Investigator or monitor will package and return all unused Test  articles to JJVC. 
If there is a discrepancy betw een the shipment documents and th e contents, contact [CONTACT_35501] 
CR-5913 v2.0, Amendment 1.0 Page 24 of 183 JJVC CONFIDENTIAL
9&7 of 15 minutes.
1.21 Toric Fit
Evaluation (if 
applicable)The principal or Co-Investigator will evaluate the toric fit after lens settling and record:â€¢ The rotational position to the nearest degree â€¢ Lens stability with blinkâ€¢ Lens stability with eye versions â€¢ Toric fit acceptable or unacceptable Toric lens fit will be unacceptable if lenses rotated more than 40 degrees, or lens stability is worse than 5 degrees  movement with blink.  
If toric fit is unacceptabl e, remove the lenses, 
perform biomicroscopy and proceed to final evaluation.
1.22 Lens Fit
AssessmentThe principal or Co-Investigator will evaluate the general lens fit.  Le ns fit will be assessed in 
primary gaze, upgaze & Josephson push up test.An unacceptable lens fit will be any one or more of the following: 
â€¢ presence of limbal exposure (appearance of 
clear cornea) in any gazeâ€¢ presence of edge liftâ€¢ Presence of unacceptable movement (excessive or insuffi cient) in all three 
movement categories (primary gaze, upgaze, and push-up). 
If either lens is deemed unacceptable, the 
subject   will   be   discontinued   from   the study.  Perform a slit- lamp evaluation and 
complete the Final Evaluation
1.[ADDRESS_816259] the results will not be recorded.  Appendix G/HAcuvue Fitting Guide 
1.24 Modifications (if 
necessary)The ECP will modify the lenses based upon the subjectâ€™s responses in accordance with the Fitting Guide. Two Modifications allowed. If Appendix G/HAcuvue 
CR-5913 v2.0, Amendment 1.0 Page 29 of 183 JJVC CONFIDENTIAL
9&7 discretion of the Inves tigator, rinse the 
subjectâ€™s eyes thoroughly with preservative-
free saline.
U.[ADDRESS_816260]â€™s exit distance visual  
acuity (OD, OS and OU) to the nearest letter with the subjects wearing the study provided spectacle glasses. 
 /DERUDWRU\ 3URFHGXUHV
Not Applicable 
 68%-(&76&203/(7,21:,7+'5$:$/
 &RPSOHWLRQ&ULWHULD
Subjects are considered to have c ompleted the study if they:  
xprovided informed consent;  
xthey are eligible;
xhave not withdrawn/discontinued f or any reason described in Sec tion 8.2; 
xComplete all study visits
 :LWKGUDZDO'LVFRQWLQXDWLRQ IURPWKH 6WXG\
A subject will be withdrawn from the study for any of the follo wing reasons:
xSubject death during the study period 
xSubject withdrawal of consent 
xSubject not complia nt to protocol  
xSubject lost to follow-up  
xSubject no longer meets eligibilit y criteria (e.g. the subject becomes pregnant)
xSubject develops significant or s erious adverse events causing discontinuation of 
study lens wear  
xSubjects who have experienced a C orneal infiltrative Event (CIE )
xInvestigatorâ€™s clinical judgment regarding the subject safety reasons (that it is in the 
best interest of the subject to stop treatment)
xSubject not compliant with s tudy lens wear schedule
xSubject not successfully dispens ed due to lack of efficacy and safety including poor 
vision, poor comfort or u nacceptable fit
For discontinued subjects, the Investigator will: 
xComplete the current visit (scheduled or unscheduled) 
xComplete the Final Evaluation, indicating the reason that the s ubject was 
discontinued from the study 
xRecord the spherocylindrical ref raction with best corrected dis tance visual acuity  
CR-5913 v2.0, Amendment 1.0 Page 32 of 183 JJVC CONFIDENTIAL
9&7 xCollect used Test article(s) (worn or brought to the visit) from the subject and discard 
them, unless otherwise stated in Section 7.[ADDRESS_816261] article(s) from the subject 
An additional subject may be enrolled if a subject discontinues from the study prematurely.  
In cases where a subject is lost to follow-up, every possible effort must be made to contact 
[CONTACT_615571]/withdr awal.  The measures taken to 
follow up must be documented including two written attempts and  a certified letter (or 
equivalent) as the final attempt. 
 35(678'< $1' &21&20,7$17 ,17(59(17,210(',&$7,21
Concomitant medications will be documented during screening and  updated during the study.  
Disallowed medications for this study include: Any ocular medic ations with the exception of 
rewetting drops.Concomitant therapi[INVESTIGATOR_35443]: Any therapi[INVESTIGATOR_615549]. 
 '(9,$7,216 )520 7+([ZIP_CODE]&2/
Investigator will notify study sponsor upon identification of a  protocol deviation. Major 
protocol deviations must be reported to the sponsor within 24 hours after discovery of the protocol deviation.  The Investigator will report deviations pe r IRB/IEC requirements. All 
deviations will be tr acked and corrective ac tions implemented a s appropriate.  
If it becomes necessary for the  Investigator to implement a dev iation in order to eliminate an 
immediate hazard to the trial subject, the Investigator may imp lement the deviation 
immediately without notification to the sponsor. Within 24 hour s after the implemented 
deviation, the Investigator mus t notify and provide the rationa le to the Sponsor and, as
required, the IEC/IRB.  
 678'< 7(50,1$7,[ADDRESS_816262] lens group develop serious expected 
(e.g., definite or probable MK) or unexpected device related ad verse events, the study will be 
suspended. Upon review and consu ltation with IRB, and JJVC safe ty review committee, the 
study may be terminated. The occurrence of one or more Unanticipated Serious Adverse Devi ce Effect ([LOCATION_003]DE), or 
any SAE where the relationship to study agent cannot be ruled o ut, may result in stoppi[INVESTIGATOR_615550].  In the event of a [LOCATION_003]DE or  SAE, the Sponsor may 
unmask the treatment regimen for the subject(s) and will discuss  this with the Investigator 
before any further s ubjects are enrolled.
CR-5913 v2.0, Amendment 1.0 Page 33 of 183 JJVC CONFIDENTIAL
9&7 The Sponsor will determine when a  study will be stopped.  The Pr incipal Investigator always 
has the discretion to initiate stoppi[INVESTIGATOR_615551]â€™s res ults are compromised. 
JJVC reserves the right to terminate the study at any time for a ny reason.  Additionally, the 
IEC/IRB reserves the right to terminate the study if an unreaso nable risk is determined.  The 
study can be terminated by [CONTACT_079] [INVESTIGATOR_615552], if in their opi[INVESTIGATOR_1649], after a di scussion with JJVC, it is 
determined that it w ould be unwise to continue  at the clinical site.   
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events.  If it is  
determined that an adverse event presents an unreasonable risk,  the investigation, or that part 
of the investigation presenting the risk, will be terminated, a s soon as possible. 
Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulato ry Authority as required by [CONTACT_19566] l regulatory requirements.
 352&('85()25+$1'/,1* 352'8&7 48$/,7< &203/$,[ADDRESS_816263] Quality Complaint (PQC ) refers to any written, electr onic, or oral communication 
that alleges deficiencies related to the identity, quality, dur ability, reliability, safety, 
effectiveness or performance of Test articles after they have be en released for clinical trial 
use.   
Potential complaints may come from a variety of sources includi ng but not limited to 
subjects, clinical research associates (CRA), clinical operatio ns managers (COM), medical 
monitors, and site personnel, etc. The following are not conside red product quality 
complaints:
xSubject satisfaction inquiries r eported via â€œSubjective Questionnairesâ€ and â€œPatient 
Reported Outcomes (PRO)â€.
xClinical Test articles that are stored improperly or damaged af ter receipt at the 
investigational site.
xLens replacements that occu r due to drops/fall-outs. 
xDamage deemed by [CONTACT_171188] h andling by [CONTACT_28024], 
and not indicative of a quality deficiency (i.e. tears, rips, e tc.), only in situations 
where there is no deficiency alleged by [CONTACT_423]. 
Within [ADDRESS_816264] be 
recorded in the EDC system, which will trigger an automatic ema il notification to the 
appropriate COM/CRA and Clinical QA representative. In cases wh ere the EDC system in 
use is not configured to send au tomatic notifications or when an  EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery  that a PQC has occurred.   
CR-5913 v2.0, Amendment 1.0 Page 34 of 183 JJVC CONFIDENTIAL
9&7 Upon receipt of the EDC notification, the COM/CRA will contact [CONTACT_318498]:
xDate the complaint was received/recorded in the EDC System (Dat e of Sponsor 
Awareness)
xWho received the complaint 
xStudy number 
xClinical site information (c ontact name, site ID, telephone num ber) 
xLot number(s) 
xUnique Subject Identifier(s) 
xIndication of who first observed c omplaint (site personnel or s ubject) 
xOD/OS indication, along with wheth er or not the lens was insert ed 
xAny related AE number if applicable
xDetailed complaint description (scheduled/unscheduled visit, we ar time, symptoms, 
resolution of symptoms, etc.) 
xEye Care Provider objective (slit lamp) findings if applicable
xConfirmation of produc t availability for return (and tracking in formation, if 
available), or rationale if pr oduct is not available for return (Refer to 
for Test article return instructions) 
Once a complaint is received, it will be assessed by [CONTACT_19569], C RA, or trained site personnel 
to determine if it is an Adverse Event/Serious Adverse Event (AE /SAE).  If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel wi ll follow Section 13 of this 
protocol. If the AE/SAE was pot entially the result of a product  quality related deficiency, 
these procedures also applies and will be execu ted in parallel.   
In some cases, a PQC form may be generated in EDC by [CONTACT_35514].  In this event, the 
PQC forms will be marked â€œIntentionally Left Blankâ€ or â€œILBâ€.  Justification for ILB must be documented. 
 $'9(56( (9(176
'HILQLWLRQVDQG&ODVVLILFDWLRQV
$GYHUVH (YHQW $( â€“ An AE is any untoward (unwanted) medical occurrence in a patie nt 
or clinical investigation subject administered a Test article, study treatment or study 
procedure whether or not caused by [CONTACT_615572], study treat ment or procedure.  An AE 
can therefore be any unfavorable or unintended sign (including an abnormal finding), 
symptom, or disease temporally associated with the use of the T est article, study treatment, 
or study procedure whether or not related to the Test article, s tudy treatment, or study 
procedure. 
An AE includes any condition (including a pre-existing conditio n) that:
CR-5913 v2.0, Amendment 1.0 Page 35 of 183 JJVC CONFIDENTIAL
9&7 1. Was not present prior to the study , but appeared or reappear ed following initiation of 
the study 
2. Was present prior to the study, but worsened during the study . This would include 
any condition resulting from concomitant illnesses, reactions to concomitant 
medications, or progressi on of disease states  
3. Pregnancy must be documented as an adverse event and must be reported to the 
clinical monitor and to the Sponsor immediately upon learning of the event 
6HULRXV$GYHUVH(YHQW 6$( â€“ An SAE is any untoward m edical occurrence that:
xResults in death
xIs life threatening
xRequires in-patient hospi[INVESTIGATOR_318492]/incapacity (e.g ., a sight threatening 
event, a significant persistent or permanent change, impairment , damage, or 
disruption to the subjectâ€™s body)
xIs a congenital anomaly/birth defect, or
xRequires intervention to prevent p ermanent damage (the use of t he Test article
resulting in a condition which requires medical or surgical int ervention to preclude 
permanent impairment of the body structure or a body function).   Important medical 
events that may not result in death, be life-threatening, or re quire hospi[INVESTIGATOR_71154], base d upon appropriate medical judgment, they may 
jeopardize the patient or subject and may require medical or sur gical intervention to 
prevent one of the outcomes listed in the above definition. 
Diagnoses and conditions that are considered Ocular Serious Adv erse Events include, but not 
limited to: 
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber) 
xPermanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines or greater
xCentral Corneal Opacity
xCentral Corneal Neovascularization
xUveitis
xEndophthalmitis 
xHypopyon 
xHyphemia
xPenetration of Bow manâ€™s Membrane 
xPersistent Epi[INVESTIGATOR_615553]-5913 v2.0, Amendment 1.0 Page 36 of 183 JJVC CONFIDENTIAL
9&7 6LJQLILFDQW $GYHUVH (YHQWV  â€“ Those events that are usually symptomatic and warrant 
discontinuation (temporary or permanent) of the Test article (ex cluding Serious Adverse
Events).   
Diagnoses and conditions that are considered Ocular Significant Adverse Events include, but 
not limited to the following: 
xContact [CONTACT_19571] (CLPU) 
xSignificant Infiltrative Events (SIE)
xSuperior Epi[INVESTIGATOR_32955] (SEALs)
xAny Temporary Loss of > [ADDRESS_816265] lens related corneal  events - e.g. Epi[INVESTIGATOR_19533] (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates temporary lens discontinua tion > 2 weeks 
1RQ6LJQLILFDQW $GYHUVH (YHQWV  â€“ Those conditions that are usually asymptomatic and 
usually do not warrant disconti nuation (temporary or permanent)  of the Test article.
However, the Investigator may choose to treat as a precautionar y measure.  
Diagnoses and conditions that are considered Ocular Non-Signifi cant Adverse Events 
include, but not limited to the following: 
xNon-significant Infiltrative Event (NSIE)
xContact [CONTACT_19573][INVESTIGATOR_19534] (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact [CONTACT_171190],
which necessitates temporary lens discontinuation < 2 weeks 
$GYHUVH 'HYLFH (IIHFW $'( â€“ A sub-set of AEs, and include only those adverse events 
that are cause by [CONTACT_615573] d to the investigational device.
8QDQWLFLSDWHG $GYHUVH 'HYLFH (IIHFW 8$'( â€“ Any serious adverse effect on health or 
safety or any life-threatening problem or death caused by, or a ssociated with, the Test article,
if that effect, problem, or death was not previously identified  in nature, severity, or degree of 
incidence in the investigational plan, Investigatorâ€™s Brochure or protocol, or any other 
unanticipated serious problem associated with the Test article t hat relates to the rights, safety 
and welfare of subjects.
CR-5913 v2.0, Amendment 1.0 Page 37 of 183 JJVC CONFIDENTIAL
9&7 $VVHVVLQJ $GYHUVH (YHQWV
In conjunction with the medical monitor, the Investigator will evaluate adverse events to 
ensure the events are categori zed correctly.  Elements of categ orization will include:
xSeriousness/Classifications ( see definition in Section 13.1) 
xCausality or Relatedness â€“ i.e. t he relationship between the Tes t article, study 
treatment or study procedures and the adverse event (not related; unlikely related; 
possibly related; related -  see definition in Section 13.2.1) 
xAdverse Event Severity â€“ Adverse event severity is used to assess  t h e  d e g r e e  o f  
intensity of the adverse event (mild; moderate; severe for all events - see definition in 
Section 13.2.2).  
xOutcome â€“ Not Recovered or Not Res olved; Recovering or Resolving;  Recovered or 
Resolved with Sequelae; Recovered or Resolved; Death Related to Adverse Event;
Unknown 
xActions Taken â€“ None; temporarily discontinued; permanently disco ntinued; other 
action taken
 &DXVDOLW\ $VVHVVPHQW
&DXVDOLW\ $VVHVVPHQW â€“ A determination of the relati onship between an adverse event and 
the Test article, study treatment , or study procedure. The Test  article, study treatment or 
study procedure relationship for each adverse event shall be determined by [CONTACT_394140]: 
xNot Related- An adverse event that is not related to the use of  the Test article, study 
treatment or study procedures. 
xUnlikely Related â€“ An adverse event for which an alternative ex planation is more 
likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time 
suggests that a causal relationship is not likely. 
xPossibly Related â€“ An adverse event that might be due to the us e of the Test article, 
or to the study treatment or study procedures. An alternative explanation, e.g. concomitant treatment, concomitant disease(s), is inconclusive.   The relationship in 
time is reasonable.  Therefore, the causal relationship cannot be excluded.
xRelated â€“ An adverse event that is listed as a possible adverse effect (device) or 
adverse reaction (drug) and cannot be reasonably explained by a n alternative 
explanation, e.g. concomitant tr eatment of concomitant disease( s).  The relationship 
in time is very suggestive, e.g. it is confirmed by [INVESTIGATOR_5328]-challeng e and re-challenge. 
 6HYHULW\ $VVHVVPHQW
6HYHULW\ $VVHVVPHQW â€“ A qualitative assessment of the degree of intensity of an adver se 
event as determined by [CONTACT_19577]/her by [CONTACT_423].  The 
assessment of severity is made irrespective of Test article, st udy treatment or study procedure 
relationship or seriousness of the event and should be evaluate d according to the following 
scale:
CR-5913 v2.0, Amendment 1.0 Page 38 of 183 JJVC CONFIDENTIAL
9&7 xMild â€“ Event is noticeable to the subject, but is easily tolerat ed and does not interfere 
with the subjectâ€™s daily activities
xModerate â€“ Event is bothersome, possible requiring additional th erapy, and may 
interfere with the subjectâ€™s daily activities
xSevere â€“ Event is intolerable, n ecessitates additional therapy o r alteration of therapy 
and interferes with the s ubjectâ€™s daily activities
'RFXPHQWDWLRQDQG)ROORZ8SRI $GYHUVH (YHQWV
The recording and documenting of  adverse events (ocular and non -ocular) begins when the 
subjects are exposed to the Test article, study treatment or st udy procedure.  Adverse events 
reported before the use of Test article, start of study treatme nt, or study procedures will be 
recorded as medical history. Ho wever, if the condition deterior ates at any time during the 
study it will be recorded and reported as an AE. Untoward medica l events reported after the 
subjectâ€™s exit from the study will be recorded as adverse events at the discretion of the 
Investigator. 
Upon finding an adverse event, the Principal Investigator [INVESTIGATOR_19535]. He /she will complete the Advers e Event /eCRF.  
Complete descriptions of all adverse events must be available in  the subject record. All 
Adverse Events including local a nd systemic reactions not meeti ng the criteria for â€œserious 
adverse eventsâ€ shall be captured on the appropriate case report  form or electronic data 
system. All adverse events occurring while the subject is enrolled in the study must be 
documented appropriately regardless of relationship.   
It is the Investigatorâ€™s responsibility to maintain documentati on of each reported adverse 
event. All adverse events will be followed in accordance with a pplicable licensing 
requirements.  Such documentati on will include the following: 
xAdverse event (diagnosis not symptom) 
xDrawings or photographs (where appropriate) that detail the fin ding (e.g., size, 
location, and depth, etc.) 
xDate the clinical  site was notified 
xDate and time of onset
xDate and time of resolution
xAdverse event classification, s everity, and relationship to Tes t articles, as applicable
xTreatment regimen instituted, including concomitant medications  prescribed, in
accordance with applicable licensing requirements
xAny referral to another hea lth care provider if needed
xOutcome, ocular damage (if any)
xLikely etiology
xBest corrected visual acuity at the discovery of the event and upon conclusion of the 
event
CR-5913 v2.0, Amendment 1.0 Page 39 of 183 JJVC CONFIDENTIAL
9&7 In addition, if an infiltrate(s) is present, he/she will comple te the Corneal Infiltrate 
Assessment /eCRF.  Where necessary, a culture of the corneal le sion will be collected to 
determine if the infection is microbial in nature.  If cultures  are collected, the date of culture 
collection and laboratory  utilized will be recorded.  
Changes in the severity of an AE shall be documented to allow an assessment of the duration 
of the event at each level of intensity to be performed.  Adver se events characterized as 
intermittent require documentation of the onset and duration of  each epi[INVESTIGATOR_1865]. Changes in the 
assessment of relationship to the  Test Article shall also be cle arly documented.
Subjects who present with an adverse event shall be followed by  [CONTACT_737], within
licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or been satisfactorily resolved.  If further treatment beyond licensure is required, the patient will be referred to the appropriate  health care provider.  The Inves tigator will use his/her clinical 
judgment as to whether or not a  subject reporting with an adver se event will continue in the 
study.  If a subject is discontinued from the study, it will be  the responsibility of the 
Investigator to record the reason for discontinuation.  The Investigator will also document the adverse event appropriately and complete the Adverse Event /eCRF . Any subjects with 
ongoing adverse events related to the Test article, study treat ment or study procedures,  as of 
the final study visit date should be followed to resolution of the adverse event or until referral 
to an appropriate healt h care provider, as recommended by [CONTACT_737]. 
5HSRUWLQJ $GYHUVH (YHQWV
The Investigator will notify the Sponsor of an adverse event by  e-mail, facsimile, or 
telephone as soon as possible and no later than 24 hours from discovery for any serious /significant adverse events, and 2 days from discovery for any non-significant adverse event.  
In addition, a written report will be submitted by [CONTACT_39725] l Investigator to the IEC/IRB 
according to their requirement s (Section 13.4.2). The report will  comment whether or not the 
adverse event was considered to be related to the Test article,  s t u d y  t r e a t m e n t  o r  s t u d y  
procedures. 
13.4.1 5HSRUWLQJ $GYHUVH (YHQWVWR 6SRQVRU
6HULRXV6LJQLILFDQW$GYHUVH(YHQWV
The Investigator will inform the sponsor of all serious/signifi cant adverse events occurring 
during the study period as soon as possible by e-mail, fax, or telephone, but no later than 24 
hours following discovery of the event.  The Investigator is ob ligated to pursue and obtain 
information requested by [CONTACT_35519]. 
All subjects experiencing a serious/significant adverse event mu st be followed up and all 
outcomes must be reported. 
CR-5913 v2.0, Amendment 1.0 Page 40 of 183 JJVC CONFIDENTIAL
9&7 When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject received.  The S ponsor and study monitor should 
be notified prior to unmasking the Test articles.
In the event of a serious/significant adverse event, the Investi gator must:
xNotify the Sponsor immediately
xObtain and maintain in the subjectâ€™s records all pertinent medic al information and 
medical judgment for colleagues who assisted in the treatment a nd follow-up of the 
subject
xProvide the Sponsor with a complete case history which includes  a statement as to 
whether the event was or was not  related to the use of the Test article
xNotify the IEC/IRB as required by [CONTACT_6179]/IRB reporting procedure  according to 
national regulations 
8QDQWLFLSDWHG 6HULRXV$ GYHUVH'HYLFH(IIHFW8$'(
In the event of an Unanticipated (Serious) Adverse Device Effec t (UADE), the Investigator 
will submit a report of the UADE to the Sponsor and IEC/IRB as s oon as possible, but no 
later than [ADDRESS_816266] rep ort the results of the 
evaluation to FDA, the IEC/IRB and participating Investigators within [ADDRESS_816267]. 
1RQ6HULRXV$GYHUVH(YHQWV
All non-serious adverse events, including non-serious adverse d evice effects, will be reported 
to the sponsor by [CONTACT_35521] 2 days from di scovery. 
13.4.2 5HSRUWLQJ $GYHUVH (YHQWVWR WKH 5HVSRQVLEOH ,(&,5% DQG+HDOWK $XWKRULWLHV
Adverse events that meet the I EC/IRB requirements for reporting must be reported within the 
IEC/IRBâ€™s written guidelines. Each clinical site will refer to and follow any guidelines set 
forth by [CONTACT_19581]/IRB. Each clinical site will refer to and follow any guidelines 
set forth by [CONTACT_19582].
The Sponsor will report applicable Adverse Events to the local h ealth authorities according 
the written guidelines, including reporting timelines.
(YHQW RI 6SHFLDO ,QWHUHVW
None 
CR-5913 v2.0, Amendment 1.0 Page 41 of 183 JJVC CONFIDENTIAL
9&7 5HSRUWLQJ RI 3UHJQDQF\
Subjects reporting pregnancy (by [CONTACT_6270]-report) during the course of the study will be 
discontinued after the event is recorded as an Adverse Event.  Once discontinued, pregnant 
participants and their fetuses will not be monitored for study related purposes.  At the 
Investigatorâ€™s discretion, the study participant may be followe d by [CONTACT_615574]. However, this data will not be collected as part of the clinical study database.  
Pregnant participants are not discontinued from contact [CONTACT_89631], but due to genera l concerns relating to pregna ncy and contact [CONTACT_19584].  
Specifically, pregnant women are  discontinued due to fluctuatio ns in refractive error and/or 
visual acuity that occur secondary  to systemic hormonal changes , and not due to unforeseen 
health risks to the mother or fetus. 
 67$7,67,&$/ 0(7+2'6
*HQHUDO&RQVLGHUDWLRQV
All data summaries and statistical analyses will be performed u s i n g  t h e  S A S  s o f t w a r e  
Version 9.4 (SAS Institute, Cary, NC). Throughout the analysis of data, the results for each 
subject/eye will be used when available for summarization and s tatistical analysis.  
Unscheduled visits will be summarized separately and will be ex cluded from the statistical 
analysis.
Summary tables (Descriptive statistics and/or frequency tables)  will be provided for all 
baseline variables, efficacy variables and safety variables as appropriate.  Continuous 
variables will be summarized with descriptive statistics (n, me an, standard deviation (SD), 
median, minimum and maximum). Fr equency count and percentage of  subjects or eyes 
within each category will be pr ovided for categorical data.
Summaries will be presented by [CONTACT_171192]. All analyses will be conducted on per-protocol population (see section 
14.3).   
6DPSOH 6L]H -XVWLILFDWLRQ
There will be one testing site: VRC ( ).  A total of approximate ly [ADDRESS_816268] to the primary endpoint.   
CR-5913 v2.0, Amendment 1.0 Page 42 of 183 JJVC CONFIDENTIAL
9&7 Using the POWER procedure in SAS 9.4, below is the summary of s ample size required 
based on the different assumptions of the true percentage of su bjects with at most one 
modification.  
xPercentage of subjects wit h at most one modification 
True Percentage (%) # of subjects needed Power
70 56 0.913
75 35 0.924
80 23 0.928
$QDO\VLV3RSXODWLRQV
Not Applicable 
6DIHW\ 3RSXODWLRQ
All subjects who were administered any Test article excluding s ubjects who drop out prior to 
administering any Test article. At least one observation should be recorded. 
3HU3URWRFRO 3RSXODWLRQ
All subjects who have successfully completed all visits and did  not substantially deviate from 
the protocol as determined by [CONTACT_19588] 
(Per-Protocol Population). Jus tification of excluding subjects with protocol deviations in the 
per-protocol population set will  be documented in a memo to fil e. 
,QWHQWWR7UHDW,[ADDRESS_816269] one observation should be recorded. 
/HYHORI 6WDWLVWLFDO6LJQLILFDQFH
All planned analysis for this  study will be conducted with an o verall type I error rate of 5%.  
3ULPDU\ $QDO\VLV
Primary efficacy analysis: 
Due to the potential low incidence rates of unacceptable lens f itting, summary statistics will 
be firstly used to evaluate the percentage of the subjects with  at most one optimization per-
protocol population.  Due to the potential low incidence rates of unacceptable lens f itting, summary statistics will 
be firstly used to evaluate the percentage of the subjects with  at most one optimization per-
protocol population.  
CR-5913 v2.0, Amendment 1.0 Page 43 of 183 JJVC CONFIDENTIAL
9&7 If applicable, a generalized linear mixed model with a binary d istribution and logit link 
function will be applied to the number of modifications (1=at m ost one modification; 0 = 
more than one modification).  Age, gender and subjectsâ€™ add pow er will be included in the 
model as fixed effects when appropriate. ECP and subject will b e included as random effect. 
The proportion of subjects with at most one optimization will be  calculated with 95% 
confidence interval. If the lower limit of the confidence inter val is greater than 50%, the 
statistical superiorit y will be concluded.
If the incidence rate is too low or there are problems with the  convergence of the above 
model, Agresti methods or Fisherâ€™s exact test for binomial prop ortion will be used to 
evaluate the confidence interval s of the corresponding endpoint s. 
6HFRQGDU\ $QDO\VLV
This is not applicable. 
2WKHU ([SORUDWRU\ $QDO\VHV
This is not applicable. 
,QWHULP$QDO\VLV
This not applicable. 
3URFHGXUH IRU +DQGOLQJ0LVVLQJ 'DWD DQG'URS2XWV
Missing or spurious values will not be imputed. The count of mi ssing values will be included 
in the summary tables and listings. 
Subject dropout is expected to be  one of the main reasons of mi ssing data in this clinical trial. 
Past clinical trials donâ€™t provide  the evidence that subject dropout is systematic or not-at-
random. To evaluate the impact of missing data, sensitivity ana lysis will be conducted using 
multiple imputation methods if the proportion of subject dropout is greater than the 15%. The 
SAS/STAT procedures PROC MI and PROC MIANALYZE will be utilized  w i t h  a  
parametric regression method used to make at least 5 imputations.
 3URFHGXUH IRU 5HSRUWLQJ 'HYLDWLRQVIURP6WDWLVWLFDO3ODQ
The analysis will be conducted according to that specified in a bove sections.  There are no 
known reasons for which it is planned to deviate from these analysis methods.  If for any 
reason a change is made, the change will be documented in the s tudy report along with a 
justification for the change.
CR-5913 v2.0, Amendment 1.0 Page 44 of 183 JJVC CONFIDENTIAL
9&7  '$7$ +$1'/,1* $1' 5(&25' .((3,1*$5&+,9,1*
(OHFWURQLF &DVH 5HSRU W )RUP'DWD &ROOHFWLRQ
The data for this study will be captured on electronic case rep ort forms (eCRFs) using 
Bioclinica Express version 5.5 EDC system). An authorized data originator will enter study 
data into the eCRFs using the EDC system. Data collected on equi pment that is not captured 
in EDC will be formatted to the specification of the JJVC databa se manager and sent to JJVC
for analysis.  
The clinical data will be recorded on dedicated eCRFs specifica lly designed to match the 
study procedures for each visit.  Once completed, the eCRFs will be reviewed for accuracy 
and completeness and signed by [CONTACT_737].  The sponsor or sponsorâ€™s representatives 
will be authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study.  
Edit checks, electronic queries, and audit trails are built int o the system to ensure accurate 
and complete data collection. Data will be transmitted from the  clinical site to a secure 
central database as forms are c ompleted or updated, ensuring information accuracy, security, 
and confidentiality. After the final database lock, the Investi gator will be provided with 
Individual Patient Pro files (IPP) including  the full audit trai l on electronic media in PDF 
format for all of the study data. The IPP must be retained in t he study files as a certified copy 
of the source data for the study.  The content and structure of the  eCRFs are compliant with ISO14 155:2011. 
6XEMHFW 5HFRUG
At a minimum, subject record shoul d be available for the follow ing:  
xsubject identification
xeligibility
xstudy identification
xstudy discussion 
xprovision of and date of  informed consent 
xvisit dates
xresults of safety and efficacy pa rameters as required by [CONTACT_318500]-up of adverse events 
xmedical history and  concomitant medication
xTest article receipt/dispensing/return records
xdate of study completion
xreason for early discontinuation of Test article or withdrawal f rom the study, if 
applicable
CR-5913 v2.0, Amendment 1.0 Page 45 of 183 JJVC CONFIDENTIAL
9&7 The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable.  The  first point of entry is consid ered to be the source record. 
Adverse event notes must be rev iewed and initialed by [CONTACT_737].
 '$7$ 0$1$*(0(17
$FFHVVWR 6RXUFH 'DWD'RFXPHQW
The Investigator/Institution will permit trial-related monitori ng, audits, IEC/IRB review and 
regulatory inspection(s) by [CONTACT_20618]/documents.  Should the clinical site be contact[CONTACT_35527]/IRB or regulato ry authority, JJVC must be 
contact[CONTACT_318502] w riting within 24 hours. 
&RQILGHQWLDOLW\ RI ,QIRUPDWLRQ
Information concerning the inve stigational product and patent a pplication processes, 
scientific data or other pertinent information is confidential and remains the property of 
JJVC.  The Investigator may use this information for the purposes of the study only. It is understood by [CONTACT_737] t hat JJVC will use information de veloped in this clinical study 
in connection with the developmen t of the investigational product and therefore may disclose 
it as required to other clinical investigators and to regulatory  agencies. In order to allow the 
use of the information derived from this clinical study, the In vestigator understands that 
he/she has an obligation to provi de complete test results and a ll data developed during this 
study to the Sponsor. 
'DWD 4XDOLW\ $VVXUDQFH
Steps will be taken to ensure the  accuracy and reliability of da ta, include the selection of 
qualified investigators and appr opriate clinical sites and revi ew of protocol procedures with 
the Principal Investigator.  The  Principal Investigator, in turn, must ensure that all Sub-
Investigators and clinical site  personnel are familiar with the  protocol and all study-specific 
procedures and have app ropriate knowledge of the study article.  
Training on case report form completion will be provided to clinic al site personnel before the 
start of the study.  The Sponsor  will review case report forms for accuracy and completeness 
remotely during the conduct of t he study, during monitoring vis its, and after transmission to 
data management.  Any data discrepancies will be resolved with the Investigator or designee, 
as appropriate.
Quality Assurance representatives from JJVC may visit clinical s ites to review data produced 
during the study and to access compliance with applicable regul ations pertaining to the 
conduct of clinical trials.  The clinical sites will provide direct access to study-related source 
data/documents and reports for the purpose of monitoring and au diting by [CONTACT_71182]. 
CR-5913 v2.0, Amendment 1.0 Page 46 of 183 JJVC CONFIDENTIAL
9&7  021,725,1*
The study monitors will maintain close contact [CONTACT_19595]â€™s designated clini cal site personnel.  The monitor â€™s responsibilities will include:
xEnsuring that the investigation is being conducted according to  t h e  p r o t o c o l ,  a n y  
subsequent amendments, and regulatory requirements are maintain ed 
xEnsuring the rights and wellbei ng of subjects are protected 
xEnsuring adequate resources, incl uding facilities, laboratories , equipment, and  
qualified clinical  site personnel
xEnsuring that protocol deviations are documented with correctiv e action plans, as 
applicable
xEnsuring that the clinical site has sufficient Test article and  supplies 
xClarifying questions regarding the study 
xResolving study issues or problems that may arise
xReviewing of study records and source documentation verification  in accordance with 
the monitoring plan 
 (7+,&$/ $1' 5(*8/$725< $63(&76
6WXG\6SHFLILF 'HVLJQ&RQVLGHUDWLRQV
Potential subjects will be fully informed of the risks and requirements of the study and, 
during the study, subjects will be given any new information th at may affect their decision to 
continue participation.  Subject s will be told that their consen t to participate in the study is 
voluntary and may be withdrawn at any time with no reason given  and without penalty or 
loss of benefits to which they would otherwise be entitled.  On ly subjects who are fully able 
to understand the risks, benefits, and potential adverse events  of the study, and provide their 
consent voluntarily will be enrolled. 
,QYHVWLJDWRU 5HVSRQVLELOLW\
The Principal Investigator [INVESTIGATOR_19536], the investigational plan,  Section 4 of the ICH E6 
guidelines on Good Clinical Practice (GCP), and applicable regu latory requirements.  GCP is 
an international ethical and scie ntific quality standard for de signing, conducting, recording, 
and reporting studies that invol ve the participation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and  well-being of study subjects are 
protected, consistent with the p rinciples of the Declaration of  Helsinki 64thWMA General 
Assembly [ADDRESS_816270] maintain 
clinical study files in accordance with Section 8 of the ICH E6 guidelines on Good Clinical 
Practice (GCP), and applicable  regulatory requirements.
CR-5913 v2.0, Amendment 1.0 Page 47 of 183 JJVC CONFIDENTIAL
9&7 ,QGHSHQGHQW (WKLFV &RPPLWWHH RU ,QVWLWXWLRQDO 5HYLHZ %RDUG ,(&,5%
Before the start of the study, the Investigator (or Sponsor whe n applicable) will provide the 
IEC/IRB with current and compl ete copi[INVESTIGATOR_19537] (where applicable): 
xFinal protocol and, if ap plicable, amendments 
xSponsor-approved informed consent form (and any other written m aterials to be 
provided to the subjects) 
xInvestigatorâ€™s Brochure (or e quivalent informa tion) and amendme nts 
xSponsor-approved subject recruitment materials
xInformation on compensation for study-related injuries or payme nt to subjects for 
participation in the study
xInvestigatorâ€™s curriculum vitae, clinical licenses, or equivalent  information (unless 
not required, as documented by [CONTACT_8134]/IRB) 
xInformation regarding funding, name [CONTACT_19618], institutional affiliations, other 
potential conflicts of interest, and incentives for subjects 
xAny other documents that the IEC/IRB requests to fulfill its obligation
This study will be undertaken only after IEC/IRB has given full  approval of the final 
protocol, amendments (if any), the informed consent form, appli cable recruiting materials, 
and subject compensation program s, and the Sponsor has received  a copy of this approval. 
This approval letter must be dated and must clearly identify th e documents being approved. 
During the study the Investigator (or Sponsor when applicable) will send the following 
documents to the IEC/IRB for the ir review and approval, where a ppropriate: 
xProtocol amendments 
xRevision(s) to informed consent form and any other written mate rials to be provided 
to subjects 
xIf applicable, new or revised s ubject recruitment materials app roved by [CONTACT_89634]-related injuries or payment to subjects for participation in the study
xInvestigatorâ€™s Brochure amendments or new edition(s) 
xSummaries of the status of the study (at least annually or at in tervals stipulated in 
guidelines of the IEC/IRB) 
xReports of adverse events that are serious, unanticipated, and associated with the Test 
articles, according to the IRBâ€™s requirements 
xNew information that may adversely affect the safety of the sub jects or the conduct of 
the study 
xMajor protocol deviations a s required by [CONTACT_6179]/IRB
xReport of deaths of subjects under the Investigator's care 
xNotification if a new Investigat or is responsible for the study  at the clinical site
xAny other requirements of the IEC/IRB
CR-5913 v2.0, Amendment 1.0 Page 48 of 183 JJVC CONFIDENTIAL
9&7 For protocol amendments that in crease subject risk, the amendme nt and applicable informed 
consent form revisions must be submitted promptly to the IEC/IR B for review and approval 
before implementati on of the change(s). 
At least once a year, the IEC/IRB will review and reapprove thi s clinical study. This request 
should be documented in writing. 
At the end of the study, the Investigator (or Sponsor where req uired) will notify the IEC/IRB 
about the study completion.  Documentation of this notification  must be retained at the 
clinical site and a copy provide d to the CRO or Sponsor as appl icable. 
,QIRUPHG&RQVHQW
Each subject must give written consent according to local requi rements after the nature of the 
study has been fully explained. The consent form must be signed  before performance of any 
study-related activity. The consent form that is used must be a pproved by [CONTACT_171195]/IRB. The informed consent is in accorda nce with principles that 
originated in the Declaration of Helsinki, current ICH and GCP guidelines, applicable 
regulatory requirements, and Sponsor policy. Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel must explain to potentia l subject the aims, methods, reasonably anticipated 
benefits, and potential hazards of the study, and any discomfor t it may entail. Subjects will be 
informed that their participation is voluntary and that they ma y withdraw consent to 
participate at any time. The subject will be given sufficient time to read the informed c onsent form and the 
opportunity to ask questions. Afte r this explanation and before entry into the study, consent 
should be appropriately recorded by [CONTACT_19720]'s date d signature. After having 
obtained the consent, a copy of the informed consent form must be given to the subject. 
3ULYDF\ RI 3HUVRQDO'DWD
The collection, processing and di sclosure of personal data and medical information related to 
the Study Subject, and personal da ta related to Principal Inves tigator and any clinical site 
personnel (e.g., name, clinic addr ess and phone number, curricu lum vitae) is subject to 
compliance with the Data Protec tion Act of [ADDRESS_816271] these data, to maintain the confidentiality of the pe rsonâ€™s related health and 
medical information, to properly inform the concerned persons a bout the collection and 
processing of their personal data, to grant them reasonable acc ess to their personal data and 
to prevent access by [CONTACT_35532]. All information obtained during the course of the investigation  will be regarded as 
confidential. All personal data gathered in this trial will be treated in strictest confidence by 
[CONTACT_240316]-5913 v2.0, Amendment 1.0 Page 49 of 183 JJVC CONFIDENTIAL
9&7 Investigators, monitors, Sponsorâ€™s personnel and IEC/IRB.  No d ata will be disclosed to any 
third party without the express permission of the subject conce rned, with the exception of 
Sponsor personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of 
their investigation related activities that, as part of the investigation will have access to the CRFs and subject records.
The collection and processing o f personal data from subjects en rolled in this study will be 
limited to those data that are necessary to investigate the efficacy, safety, quality, and utility 
of the investigational pro duct(s) used in this study. 
These data must be collected and processed with adequate precau tions to ensure 
confidentiality and compliance w ith applicable data privacy protection laws and regulations. 
The Sponsor ensures that the personal data will be: 
xprocessed fairly and lawfully 
xcollected for specified, explicit, and legitima te purposes and not further processed in a 
way incompatible with these purposes 
xadequate, relevant , and not excessive i n relation to said purpo ses 
xaccurate and, where necessary, kept current
Explicit consent for the processing of personal data will be ob tained from the participating 
subject before collection of dat a. Such consent should also add ress the transfer of the data to 
other entities and to other countries. 
The subject has the right to request through the Investigator a ccess to his personal data and 
the right to request rectification of any data that are not correct or complete . Reasonable steps 
should be taken to respond to such a request, taking into consi deration the nature of the 
request, the conditions of the stu dy, and the applicable laws a nd regulations. 
Appropriate technical and organiza tional measures to protect th e personal data against 
unauthorized disclosures or acce ss, accidental or unlawful dest ruction, or accidental loss or 
alteration must be put in place.  Sponsor personnel whose responsibilities require access to 
personal data agree to keep the i dentity of study subjects conf idential 
 678'< 5(&25'5(7(17,21
In compliance with the ICH/GCP g uidelines, the Investigator/Ins titution will maintain all 
CRFs and all subject records tha t support the data collected fr om each subject, as well as all 
study documents as specified in ICH/GCP Section 8, Essential Doc uments for the Conduct of 
a Clinical Trial, and all study documents as specified by [CONTACT_3605](s). The Investigator/Institution will take measures  to prevent accidental or 
premature destruction of these documents. 
CR-5913 v2.0, Amendment 1.0 Page 50 of 183 JJVC CONFIDENTIAL
9&7 Essential documents must be retained until at least [ADDRESS_816272]. These 
documents will be retained for a longer period if required by t he applicable regulatory 
requirements or instructed by [CONTACT_1034]. It is the responsibi lity of the Sponsor to inform the 
Investigator/Institution as t o when these documents no longer n eed to be retained. 
If the responsible Investigator r etires, relocates, or for othe r reasons withdraws from the 
responsibility of keepi[INVESTIGATOR_8090], custody must be tr ansferred to a person who will 
accept the responsibility. The Sponsor must be notified in writing of the name [CONTACT_19619]. Under no circum stance shall the Investigator relocate or dispose of any 
study documents before having  obtained written approval from th e Sponsor. 
If it becomes necessary for the Sponsor or the appropriate regu latory authority to review any 
documentation relating to this st udy, the Investigator must per mit access to such reports. 
If the Investigator has a questi on regarding retention of study  records, he/she should contact 
[CONTACT_19599]. 
 ),1$1&,$/ &216,'(5$7,216
Remuneration for study services and expenses will be set forth in detail in the Investigatorâ€™s 
Research Agreement. The Research Agreement will be signed by [CONTACT_100615] 
[INVESTIGATOR_1238] a JJVC management representa tive prior to study initiation.
Case Report Forms will be completed in real time according to th e  s t u d y  p r o c e d u r e s  specified in the study protocol.  Case Report Forms should be co mpleted and reviewed and 
signed as applicable by [CONTACT_13658] [ADDRESS_816273] 
be addressed with complete res ponses within 3 days of generation.  JJVC reserves the right to 
withhold remuneration until thes e activities are addressed.
JJVC reserves the right to withhold remuneration for costs assoc iated with protocol 
violations such as: 
xContinuing an ineligible subject in the study 
xScheduling a study visit outside  the subjectâ€™s acceptable visit  range 
 38%/,&$7,21
This study will be registered on C linicalTrials.gov by [CONTACT_19457]
5()(5(1&(6
None. 
CR-5913 v2.0, Amendment 1.0 Page 51 of 183 JJVC CONFIDENTIAL
9&7 $33(1',;$ 3$7,(17 5(3257('287&20(6 678'<48(67,211$,5(6
CR-5913 v2.0, Amendment 1.0 Page 52 of 183 JJVC CONFIDENTIAL
9&7 $33(1',;% 3$7,(17 ,[ZIP_CODE]&7,21*8,'(
Not Applicable: Non-Dispensing Study 
CR-5913 v2.0, Amendment 1.0 Page 58 of 183 JJVC CONFIDENTIAL
9&7 $33(1',;& 3$&.$*( ,16(57 $[ZIP_CODE]('352'8&7
1-Day AcuvueÂ® Moist Brand Multifocal Contact [CONTACT_615575]: Not Applicable 
CR-5913 v2.0, Amendment 1.0 Page 59 of 183 JJVC CONFIDENTIAL
3 
 DESCRIPTION 
The 1-DAY ACUVUEÂ® MOISTÂ® Brand Contact [CONTACT_32993], 1-DAY ACUVUEÂ® MOISTÂ® Brand Contact [CONTACT_615576], and 1-DAY ACUVUEÂ® MOISTÂ® Brand MULTIFOCAL Contact [CONTACT_615577] (hydrophilic) 
contact [CONTACT_615578], toric, and multifocal lenses and include LACREONÂ® Technology.    
The lens material (etafilcon A) is a copolymer of 2-hydroxyethyl methacrylate and methacrylic acid 
cross-linked with 1, 1, 1-trimethylol propane trimethacrylate and ethylene glycol dimethacrylate. These 
lenses are tinted blue using Reactive Blue Dye #4 to make the lenses more visible for handling. 
A benzotriazole UV absorbing monomer is used to block UV radiation. The UV Blocking averages 97% in 
the UVB range of 280 nm to 315 nm and 82% in the UVA range of 316 nm to 380 nm. 
Lens Properties: 
The physical/optical properties of the lens are: 
x Specific Gravity (calculated):   0.98 â€“ 1.13 
x Refractive Index:   1.40 
x Light Transmittance:  85% minimum 
x Surface Character:   Hydrophilic 
x Water Content:   58% 
x Oxygen Permeability: 
VALUE METHOD 
21.4 x 10-11 (cm2/sec) 
(ml O 2/ml x mm Hg) @ 35Â°C Fatt (boundary corrected, edge corrected)  
28.0 x 10
-11 (cm2/sec) 
(ml O 2/ml x mm Hg) @ 35Â°C Fatt (boundary corrected, non-edge corrected) 
  
CR-5913 v2.0, Amendment 1.0 Page 62 of 183 JJVC CONFIDENTIAL
4 
 AVAILABLE LENS PARAMETERS 
The 1-DAY ACUVUEÂ® MOISTÂ® Contact [CONTACT_615579]: 
x Diameter:    14.2 mm  
x Center Thickness:   0.084 mm to 0.230 mm (varies with power) 
x Base Curve:   8.5 mm, 9.0 mm 
x Powers:     -0.50D to -6.00D (in 0.25D increments) 
    -6.50D to -12.00D (in 0.50D increments) 
    +0.50D to +6.00D (in 0.25D increments) 
The 1-DAY ACUVUEÂ® MOISTÂ® Contact [CONTACT_615580]: 
x Diameter:    14.5 mm  
x Center Thickness:   0.090 mm to 0.189 mm (varies with power) 
x Base Curve:   8.5 mm  
x Powers:     Plano to -6.00D (in 0.25D increments) 
    -6.50D to -9.00D (in 0.50D increments) 
    Cylinders:  -0.75D, -1.25D, -1.75D 
Axis:  10Â°, 20Â°, 60Â°, 70Â°, 80Â°, 90Â°, 100Â°, 110Â°, 120Â°, 160Â°, 170Â°, 
180Â°  
 Plano to -6.00D (in 0.25D increments) 
    -6.50D to -9.00D (in 0.50D increments) 
    Cylinder:  -2.25D 
Axis:  20Â°, 90Â°, 160Â°, 180Â°   
+0.25D to +4.00D (in 0.25D increments) 
    Cylinders:  -0.75D, -1.25D, -1.75D 
Axis:  20Â°, 70Â°, 90Â°, 110Â°, 160Â°, 180Â°  
The 1-DAY ACUVUEÂ® MOISTÂ® MULTIFOCAL Contact [CONTACT_615581]: 
x Diameter:    14.3 mm  
x Center Thickness:   0.084 mm to 0.197 mm (varies with power) 
x Base Curve:   8.4 mm  
x Powers:     +6.00D to -9.00D (in 0.25D increments) 
x ADD Powers:   +1.25 (LOW), +1.75 (MID), +2.50 (HGH) 
  
CR-[ADDRESS_816274] lens 
solutions (i.e., rewetting drops) that contain chemicals or preservatives (such as mercury or 
Thimerosal, etc.) to which some people may develop an allergic response 
x Allergic reactions of ocular surfaces or adnexa that may be induced or exaggerated by [CONTACT_35543]  
x Any active corneal infection (bacterial, fungal, protozoal, or viral) 
x If eyes become red or irritated  
WARNINGS 
Patients should be advised of the following warnings pertaining to contact [CONTACT_13279]: 
 
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP RAPI[INVESTIGATOR_253413]; IF THE PATIENT EXPERIENCES:  
x Eye Discomfort, 
x Excessive Tearing, 
x Vision Changes, 
x Loss of Vision, 
x Eye Redness, or 
x Other Eye Problems  
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY REMOVE THE LENSES, AND PROMPTLY CONTACT [CONTACT_35546].  
When prescribed for daily wear, patients should be instructed not to wear  lenses while sleepi[INVESTIGATOR_007].  Clinical 
studies have shown that the risk of serious adverse reactions is increased when lenses are worn 
overnight, and that the risk of ulcerative keratitis is greater for extended wear contact [CONTACT_615582].
[ADDRESS_816275] lenses and lens care products are essential for 
the safe use of these products. 
The overall risk of ulcerative keratitis may be reduced by [CONTACT_253446]. 
3New England Journal of Medicine, September 21, 1989; 321 (12), pp. 773-783  
  
CR-5913 v2.0, Amendment 1.0 Page 66 of 183 JJVC CONFIDENTIAL
8 
 Specific Instructions for Use and Warnings: 
x Water Activity 
Instruction for Use Do not expose contact [CONTACT_35551].  
WARNING:  
Water can harbor microorganisms that can le ad to severe infection, vision loss, or 
blindness.  If lenses have been submersed in water when participating in water sports or 
swimming in pools, hot tubs, lakes, or oceans, the patient should be instructed to discard 
them and replace them with a new pair. The Eye Care Professional should be consulted for 
recommendations regarding wearing lenses during any activity involving water.
 
PRECAUTIONS 
Special Precautions for Eye Care Professionals:  
x Due to the small number of patients enrolled in clinical investigation of lenses, all refractive 
powers, design configurations, or lens parameters available in the lens material are not 
evaluated in significant numbers. Consequently, when selecting an appropriate lens design and parameters, the Eye Care Professional should consider all characteristics of the lens that can affect lens performance and ocular health , including oxygen permeability, wettability, 
central and peripheral thickness, and optic zone diameter. 
The potential impact of these factors on the patient's ocular health should be carefully 
weighed against the patient's need for refractive correction; therefore, the continuing 
ocular health of the patient and lens performance on the eye should be carefully monitored 
by [CONTACT_71187]. 
x Patients who wear these lenses to correct presby[CONTACT_615583] (or modified 
monovision using 1-DAY ACUVUEÂ® MOISTÂ® MULTIFOCAL Contact [CONTACT_32993]) may not achieve 
the best corrected visual acuity for either far or near vision. Visual requirements vary with 
the individual and should be considered when selecting the most appropriate type of lens for each patient.  
x Fluorescein, a yellow dye, should not be used while the lenses are on the eyes. The lenses 
absorb this dye and become discolored. Whenever fluorescein is used in eyes, the eyes should be flushed with a sterile saline solu tion that is recommended for in-eye use.  
x Eye Care Professionals should instruct the patient to remove lenses immediately if the eyes become red or irritated. 
  
CR-[ADDRESS_816276] patients about the following care regimen 
and safety precautions: 
Handling Precautions: 
x Before leaving the Eye Care Professional's offi ce, the patient should be able to promptly 
remove lenses or should have someone else available who can remove the lenses for him or 
her.  
x DO NOT  use if the sterile blister package is opened or damaged.  
x Always wash and rinse hands before handling lenses. Do not get cosmetics, lotions, soaps, creams, deodorants, or sprays in the eyes or on the lenses. It is best to put on lenses before 
putting on makeup. Water-based cosmetics are less likely to damage lenses than oil-based 
products.  
x DO NOT  touch contact [CONTACT_615584], as microscopic scratches of the lenses may occur, causing distorted vision and/or 
injury to the eye. 
x Carefully follow the handling, insertion, remova l, and wearing instructions in the "Patient 
Instruction Guide" for these lenses and those prescribed by [CONTACT_35578]. 
x Always handle lenses carefully and avoid droppi[INVESTIGATOR_35459]. 
x Never use tweezers or other tools to remove lenses from the lens container unless specifically indicated for that use. Slide the lens up the side of the bowl until it is free of the 
container. 
x Do not touch the lens with fingernails.  
Lens Wearing Precautions: 
x If the lens sticks (stops moving) on the eye, follow the recommended directions in "Care for 
a Sticking (Non-Moving) Lens.â€ The lens should move freely on the eye for the continued 
health of the eye. If non-movement of the lens continues, the patient should be instructed 
to immediately consult his or her Eye Care Professional.  
x Never wear lenses beyond the period recommended by [CONTACT_35578]. 
x The patient should be advised to never allow anyone else to wear their lenses.  They have 
been prescribed to fit their eyes and to correct their vision to the degree necessary.  Sharing 
lenses greatly increases the chance of eye infections. 
x If aerosol products, such as hair spray, are used while wearing lenses, exercise caution and 
keep eyes closed until the spray has settled.  
x Avoid all harmful or irritating vapors and fumes while wearing lenses.  
Lens Care Precautions: 
x The patient should be informed that no cleaning or disinfection is needed when lenses are 
worn for daily disposable wear.  Patients should always dispose of lenses when removed and 
have spare lenses or spectacles available.  
CR-5913 v2.0, Amendment 1.0 Page 68 of 183 JJVC CONFIDENTIAL
10 
 Other Topi[INVESTIGATOR_35460]: 
x Always contact [CONTACT_615585].  
x Certain medications, such as antihistamines, decongestants, diuretics, muscle relaxants, 
tranquilizers, and those for motion sickness ma y cause dryness of the eye, increased lens 
awareness, or blurred vision. Should such conditions exist, proper remedial measures should 
be prescribed. Depending on the severity, this could include the use of lubricating drops that 
are indicated for use with soft contact [CONTACT_71189].  
x Oral contraceptive users could develop visual changes or changes in lens tolerance 
when using contact [CONTACT_13276]. Patients should be cautioned accordingly.  
x As with any contact [CONTACT_13293], follow-up visits are necessary to assure the continuing health of 
the patient's eyes. The patient should be instructed as to a recommended follow-up 
schedule. 
Who Should Know That the Patient is Wearing Contact [CONTACT_32993]? 
x Patients should inform all doctors (Health Care Professionals) about being a contact [CONTACT_35560].  
x Patients should always inform their employer of being a contact [CONTACT_35560]. Some jobs may require use of eye protection equipment or may require that the patient not wear contact 
[CONTACT_13276].  
ADVERSE REACTIONS 
The patient should be informed that the following problems may occur when wearing contact [CONTACT_13276]: 
x The eye may burn, sting and/or itch. 
x There may be less comfort than when the lens was first placed on the eye. 
x There may be a feeling of something in the eye (foreign body, scratched area). 
x There may be the potential for some temporary impairment due to peripheral infiltrates, 
peripheral corneal ulcers, or corneal erosion. There may be the potential for other 
physiological observations, such as local or generalized edema, corneal neovascularization, 
corneal staining, injection, tarsal abnormalities, iritis, and conjunctivitis; some of which are 
clinically acceptable in low amounts. 
x There may be excessive watering, unusual eye secretions, or redness of the eye. 
x Poor visual acuity, blurred vision, rainbows or halos around objects, photophobia, or dry 
eyes may also occur if the lenses are worn continuously or for too long a time. 
  
CR-[ADDRESS_816277] once a day. They 
should ask themselves: 
x How do the lenses feel on my eyes? 
x How do my eyes look? 
x Have I noticed a change in my vision? 
If the patient reports any problems, he or she should be instructed to IMMEDIATELY REMOVE THE LENS.  
If the problem or discomfort stops, the patient should discard the lens and place a new fresh lens on the eye. 
If after inserting the new lens, the problem continues, the patient should be directed to IMMEDIATELY 
REMOVE THE LENS AND CONTACT [CONTACT_35561]. 
The patient should be instructed NOT to use a new lens as self-treatment for the problem.  
The patient should be advised that when any of the above symptoms occur, a serious condition such as 
infection, corneal ulcer, neovascularization, or iritis may be present. He or she should be instructed to 
seek immediate professional identification of the problem and prompt treatment to avoid serious eye 
damage. 
GENERAL FITTING GUIDELINES 
A. Patient Selection 
Patients selected to wear these lenses should be chosen based on:  
x Motivation to wear lenses  
x Ability to follow instructions regarding lens wear  
x General health  
x Ability to adequately handle and care for the lenses  
x Ability to understand the risk a nd benefits of lens wear  
Patients who do not meet the above criteria should not be provided with contact [CONTACT_13276].  
B. Pre-fitting Examination 
Initial evaluation of the patient should begin with a thorough case history to determine if there are any contraindications to contact [CONTACT_13279]. During the case history, the patientâ€™s visual needs and 
expectations should be determined as well as an assessment of their overall ocular, physical, and mental health.  
  
CR-[ADDRESS_816278] lens es, a comprehensive ocular evaluation should be 
performed that includes, but is not limited to, the measurement of distance and near visual acuity, 
distance and near refractive prescription (including determining the preferred reading distance for 
presby[CONTACT_35562]), keratometry, and biomicroscopic evaluation.  
Based on this evaluation, if it is determined that the patient is eligible to wear these lenses, the Eye Care 
Professional should proceed to the lens fitting instructions outlined below.  
C. Initial Power Determination 
A spectacle refraction should be performed to establish the patientâ€™s baseline refractive status and to 
guide in the selection of the appropriate lens power. Remember to compensate for vertex distance if 
the refraction is greater than Â±4.00D.  
D. Base Curve Selection (Trial Lens Fitting) 
The following trial lenses should be  selected for patients regardless of keratometry readings.  However, 
corneal curvature measurements should be performed to establish the patientâ€™s baseline ocular status. 
x 1-DAY ACUVUEÂ® MOISTÂ®:   8.5 mm/14.2 mm 
x 1-DAY ACUVUEÂ® MOISTÂ® for ASTIGMATISM:   8.5 mm/14.5 mm  
x 1-DAY ACUVUEÂ® MOISTÂ® MULTIFOCAL: 8.4 mm/14.3 mm 
The trial lens should be placed on each of the patientâ€™s eyes and evaluated after the patient has 
adjusted to the lenses.  
1. Criteria of a Properly Fit Lens  
A properly fit lens will center and completely cover the cornea (i.e., no limbal exposure), have 
sufficient movement to provide tear exchange under the contact [CONTACT_35563], and be 
comfortable. The lens should move  freely when manipulated digita lly with the lower lid, and then 
return to its properly centered position when released.  
2. Criteria of a Flat Fitting Lens  
A flat fitting lens may exhibit one or more of the following characteristics: decentration, 
incomplete corneal coverage (i.e., limbal exposu re), excessive movement with the blink and/or 
edge standoff. If the lens is judged to be flat fitting, it should not be dispensed to the patient. 
CR-5913 v2.0, Amendment 1.0 Page 71 of 183 JJVC CONFIDENTIAL
13 
 3. Criteria of a Steep Fitting Lens  
 A steep fitting lens may exhibit one or more of the following characteristics: insufficient 
movement with the blink, conjunctival indentation, and resistance when pushing the lens up 
digitally with the lower lid. If the lens is judged to be steep fitting, it should not be dispensed to 
the patient. 
If the initial trial base curve is judg ed to be flat or steep fitting, the alternate base curve, if available, 
should be trial fit and evaluated after the patient has adjusted to the lens. The lens should move freely 
when manipulated digitally with lower lid, and then return to a properly centered position when released. If resistance is encountered when pushing the lens up, the lens is fitting tightly and should not be dispensed to the patient. 
E. Final Lens Power (Spherical) 
A spherical over-refraction should be performed to determine the final lens power after the lens fit is judged acceptable. The spherical over-refraction should be combined with the trial lens power to 
determine the final lens prescription. The patient shou ld experience good visual acuity with the correct 
lens power unless there is excessive residual astigmatism.  
Example 1 
Diagnostic lens: -2.00D 
 Spherical over-refraction: -0.25D 
 Final lens power: -2.25D 
 
Example 2 
Diagnostic lens: -2.00D 
 Spherical over-refraction: +0.25D  
 Final lens power: -1.75D 
If vision is acceptable, perform a slit lamp examination to assess adequate fit (centration and 
movement). If the fit is acceptable, dispense the lenses and instruct the patient to return in one week 
for reassessment (see dispensing and follow-up information in PATIENT MANAGEMENT ).  
All patients should be supplied with a copy of  the PATIENT INSTRUCTION GUIDE for these lenses. 
Copi[INVESTIGATOR_35461].acuvue.com . 
 
    
CR-[ADDRESS_816279] lenses, including 
toric lenses, there are some additional steps and/or rules to follow to assure the proper fit of toric lenses.  
 
The only new steps you must follow in prescribing the 1-DAY ACUVUEÂ® MOISTÂ® Contact [CONTACT_615586], repeatability, and drift angle of the lens axis so 
that you can prescribe the correct lens axis for your patient.  
 A. How to Determine Lens Cylinder and Axis Orientation for 1-DAY ACUVUEÂ® MOISTÂ® Contact [CONTACT_615587]  
 
1. Locate the Orientation Marks  
To help determine the proper orientation of the toric lens, youâ€™ll find two primary marks approximately 1 mm from the lens edge representing the vertical position on opposite ends of the lens at 6 and 12 oâ€™clock (Fig. 1). Because of the lensâ€™ ballasting system, either mark can 
represent the vertical position â€“ there is no â€œtopâ€ and â€œbottomâ€ as in a prism-ballasted lens. You 
donâ€™t need to view both marks to assess orientation; simply look for the 6 oâ€™clock mark as you 
would with a prism-ballasted lens. 
 Figure 1 
Youâ€™ll need a slit lamp biomicroscope with a 1 to 2 mm parallelepi[INVESTIGATOR_615554]. There are a number of techniques you can use to improve the visibility of the 6 oâ€™clock mark . Using a parallelepi[INVESTIGATOR_5836] d beam and medium 
magnification (10x or 15x), slowly pan down the lens, looking just below the direct illumination 
at the retroilluminated area. Backlighting the mark this way should make it more visible. Sometimes manipulating the lower lid may be necessary to uncover the mark.  
 
2. Observe Lens Rotation and Stability  
Observe the position and stability of the â€œbottomâ€  mark. It usually stabilizes at the 6 oâ€™clock 
position. If it does, calculation of the lens power will be straightforward. The 6 oâ€™clock position is 
not a â€œmustâ€; however, the absolute requirement is that the axis position be stable and 
repeatable.   
   
CR-5913 v2.0, Amendment 1.0 Page 73 of 183 JJVC CONFIDENTIAL
15 
 The mark may stabilize somewhat left  or right (drift) of the vertical meridian and still enable you 
to fit a toric lens for that eye, as long as the lens always returns to the same â€œdrift axisâ€ position 
after settling. The deviation can be  compensated for in the final prescription. Your objective is to 
ensure that whatever position th e initial lens assumes near 6 oâ€™clock, this position must be 
stable and repeatable. With full eye movement or heavy blink, you may see the marks swing 
away, but they must return quickly to the original stable position. If the lens does not return quickly, you may need to select a different lens.  
 
Assessing Rotation  Imagine the eye as a clock dial and every hour represents a 30Â° interval. If the orientation mark 
of the initial lens stabilizes somewhat left or ri ght of the vertical position, the final lens will 
orient on the eye with the same deviation. You can use an axis reticule in the slit lamp or use a 
line-scribed lens in a spectacle trial frame to measure or estimate the â€œdrift angleâ€ of the 
cylinder axis.  
 To compensate for this â€œdrift,â€ measure or estimate the â€œdrift,â€ then add or subtract it from the 
refractive axis to determine the correct cylinde r axis. Use the LARS (Left Add, Right Subtract) 
method to determine which direction to compensate. 
 
B. Final Lens Power 
When the diagnostic lens has its axis aligned in th e same meridian as the patientâ€™s refractive axis, a 
spherocylindrical over-refraction may be performed and visual acuity determined. However, in the case of crossed axes, such as when the diagnostic lens axis is different from the spectacle cylinder 
axis, it is not advisable to perform a full spherocylindrical over-refraction because of the difficulty in 
computing the resultant power. A spherical over-refraction without cylinder refraction may be 
performed. 
If the required cylinder correction falls between two available cylinder powers, it is recommended to 
prescribe the lower cylinder power lens. See below for instructions on how to determine the final 
lens power. 
For the Sphere  
If sphere alone or combined sphere and cylinder Rx > 4.00D, compensate for  vertex distance.  
If sphere alone or combined sphere and cylinder Rx < 4.00D, vertex compensation is not necessary. 
   
CR-[ADDRESS_816280] the axis by [CONTACT_35564]. Choose a cylinder that is Ñ‡ 0.50D from the 
refractive cylinder. 
Case Examples 
Example 1: 
Manifest (spectacle) refraction: 
O.D. -2.50 / -1.25 x 180  20/20 
O.S. -2.00 / -1.00 x 180  20/20 
Choose a diagnostic lens for each eye with axis  180Â°. Place the lens on each eye and allow a 
minimum of 3 minutes for it to equilibrate, based on the patientâ€™s initial response to the lens. 
Check the orientation of the axis mark. If the bottom  axis mark is in the 6 oâ€™clock position on both 
eyes, choose the appropriate cylinder as listed previously. Here is the Rx prescribed: 
O.D. -2.50 / -1.25 x 180   
O.S. -2.00 / -0.75 x 180   
Example 2: 
Manifest (spectacle) refraction: 
O.D. -3.00 / -1.00 x 90  20/20   
O.S. -4.75 / -2.00 x 90  20/20   
Choose a diagnostic lens of -3.00 / -0.75 x 90 for the right eye and -4.50 / -1.[ADDRESS_816281] the lens on each eye and 
allow a minimum of 3 minutes for it to equilibrate. 
Right Eye  
The orientation mark on the right lens rotates left by 10Â° from the 6 oâ€™clock position and remains 
stable in this position. 
Compensation for this rotation should be done as follows: 
Compensate the 10Â° axis drift by [CONTACT_615588].  
Here is the Rx prescribed:  
O.D. -3.00 / -0.75 x 100 
  
CR-5913 v2.0, Amendment 1.0 Page 75 of 183 JJVC CONFIDENTIAL
17 
 Left Eye 
The orientation mark on the left lens rotates right by 10Â° from the 6 oâ€™clock position and remains 
stable in this position. 
Since the manifest refraction called for a power of -4.75D, compensating for vertex distance the 
sphere is reduced by 0.25D to -4.50D. The cyli nder power will be -1.75D. Compensate for the 10Â° 
axis drift to the right by [CONTACT_506836].  
Here is the Rx prescribed:  
O.S. -4.50 / -1.75 x 80  
All patients should be supplied with a copy of  the PATIENT INSTRUCTION GUIDE for these lenses. 
Copi[INVESTIGATOR_35461].acuvue.com .  
MULTIFOCAL FITTING GUIDELINES 
A. Presby[CONTACT_253453] & Patient Education 
Multifocal contact [CONTACT_253454] (i.e., 
reading a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). Therefore, 
caution should be exercised when the patient is wearing the correction for the first time until they 
are familiar with the vision provided in visual ly challenging environments. Occupational and 
environmental visual demands should be considered. If the patient requires critical visual acuity and 
stereopsis, it should be determined by [CONTACT_615589] 
1-DAY ACUVUEÂ® MOISTÂ® MULTIFOCAL Contact [CONTACT_32993]. Wearing the  
1-DAY ACUVUEÂ® MOISTÂ® MULTIFOCAL Contact [CONTACT_615590]: 
1. Visually demanding situations such as operating potentially dangerous machinery or performing 
other potentially hazardous activities; and  
2. Driving automobiles (e.g., driving at night). Patients who cannot meet their state driverâ€™s license 
requirements with the 1-DAY ACUVUEÂ® MOISTÂ® MULTIFOCAL Contact [CONTACT_615591], OR may require that additional over-correction be prescribed.  
1-DAY ACUVUEÂ® MOISTÂ® MULTIFOCAL Contact [CONTACT_615592] 
-1.00D or greater of refractive cylinder as this level of uncorrected cylinder may lead to additional 
visual compromise.  
  
CR-5913 v2.0, Amendment 1.0 Page 76 of 183 JJVC CONFIDENTIAL
18 
 The 1-DAY ACUVUEÂ® MOISTÂ® MULTIFOCAL Contact [CONTACT_615593]:  
x Lens â€œLOWâ€ = â€œlowâ€ near ADD lens (Max ADD +1.25)  
x Lens â€œMIDâ€ = â€œmediumâ€ near ADD lens (Max ADD +1.75)  
x Lens â€œHGHâ€ = â€œhighâ€ near ADD lens (Max ADD +2.50) 
B. Initial Power Determination 
A spectacle refraction should be performed to establish the patientâ€™s baseline refractive status and 
to guide in the selection of the appropriate lens power. Remember to compensate for vertex 
distance if the refraction is greater than Â±4.00D. Determine the spherical equivalent distance 
prescription for a multifocal patient. Determine the eye dominance using one of the methods 
below: 
Method 1:   Determine which eye is the â€œsighting eye.â€ Have the patient point to an object at the 
far end of the room. Cover one eye. If the patient is still pointing directly at the 
object, the eye being used is the dominant (sighting) eye. 
 
Method 2:   Determine which eye does not accept added plus power. Place a +1.00D hand-held 
trial lens in front of one eye and then the other while the distance refractive error correction is in place for both eyes while the patient is viewing the distance visual acuity chart. The eye with the plus over it that the patient notices the greatest reduction in vision is determined to be the dominant eye. 
C. Select the Initial Trial Lens  
1. For each eye, select the trial lens distance power that is closest to the patientâ€™s distance 
spherical equivalent. Remember to compensate for vertex distance if the refraction is greater than Â±4.00D. 
2. Select the near power of the lens based on the patients ADD range as follows:  
x ADD: +0.75 to +1.25 use a â€œLOWâ€ near ADD lens on each eye  
x ADD: +1.50 to +1.75 use a â€œMIDâ€ near ADD lens on each eye  
x ADD: +2.00 to +2.50 use a â€œMIDâ€ near ADD on the dominant eye and a â€œHGHâ€ near ADD lens on the non-dominant eye 
3. Allow the lenses to settle for a minimum of 10 minutes.  
4. Assess distance and near vision binocularly and monocularly.  
5. Demonstrate the vision under various lighting conditions (normal and decreased illumination) and at distance, intermediate, and near.   
CR-[ADDRESS_816282] on distance and near vision. 
7. If vision is still unacceptable, make adjustments in power as necessary (see â€œMultifocal 
Troubleshootingâ€ below). If distance and near  vision are acceptable, perform a slit lamp 
examination to assess adequate fit (centration and movement). If fit is acceptable, dispense the lenses instructing the patient to return in one week for reassessment (see dispensing and follow up information in PATIENT MANAGEMENT ). 
D. Multifocal Troubleshooting 
Unacceptable Near Vision: 
If it has been determined that no change is required based on the over-refraction, then add +0.25D to 
the spherical power of the non-dominant eye.  
 
Unacceptable Distance Vision:  
If it has been determined that no change is required based on the over-refraction, then make the 
changes as listed below: 
x If the patient is wearing two â€œLOWâ€ ADD lenses, change the dominant eye to a 
1-DAY  ACUVUEÂ® MOISTÂ® sphere lens with a power equal to the spherical equivalent distance 
prescription. 
x If the patient is wearing two â€œMIDâ€ ADD lenses, change the ADD power in the dominant eye to 
the â€œLOWâ€ ADD power. 
x If the patient is wearing a â€œMIDâ€ ADD lens in the dominant eye and a â€œHGHâ€ ADD lens in the non-dominant eye, change the non-dominant eye to a â€œMIDâ€ ADD lens and add +0.25D to the 
distance power. 
 
E. Adaptation 
Visually demanding situations should be avoided during the initial wearing period. A patient may 
at first experience some mild blurred vision, dizziness, headaches and a feeling of slight imbalance. You should explain the adaptational symptoms to the patient. These symptoms may 
last for a brief minute or for several weeks. The longer these symptoms persist, the poorer the 
prognosis for successful adaptation. 
To help in the adaptation process, the patient can be advised to first use the lenses in a 
comfortable familiar environm ent such as in the home. 
  
CR-[ADDRESS_816283] several weeks of wear (when 
adaptation is occurring), it may be advisable for the patient to only drive during optimal driving conditions. After adaptation and success with these activities, the patient should be able to 
drive under other conditions with caution. 
All patients should be supplied with a copy of  the PATIENT INSTRUCTION GUIDE for these lenses. 
Copi[INVESTIGATOR_35461].acuvue.com. 
MONOVISION FITTING GUIDELINES 
A. Patient Selection 
Monovision Needs Assessment 
For a good prognosis, the patient should have adequately corrected distance and near visual acuity in 
each eye. The amblyopic patient with significant asti gmatism (greater than 1.00D) in one eye may not be 
a good candidate for monovision correction with these lenses. 
Occupational and environmental visual demands should be considered. If the patient requires critical 
vision (visual acuity and stereopsis), it should be determined by [CONTACT_71190]. Monovision contact [CONTACT_35568]: 
1. Visually demanding situations such as operating potentially dangerous machinery or 
performing other potentially hazardous activities; and 
2. Driving automobiles (e.g., driving at night). Patients who cannot meet their state driverâ€™s 
license requirements with monovision correction should be advised to not drive with this 
correction, OR may require that additional over-correction be prescribed. 
Patient Education 
All patients do not function equally well with mono vision correction. Patients may not perform as well 
for certain tasks with this correction as they have with spectacles (multifocal, bifocal, trifocal, readers, or 
progressives). Each patient should understand that monovision, as well as other presby[CONTACT_35569], 
can create a vision compromise that may reduce visual acuity and depth perception for distance and near tasks. Therefore, caution should be exercised. During the  
   
CR-[ADDRESS_816284] lenses provide.  
B. Eye Selection 
Generally, the non-dominant eye is corrected for near vision. The following two methods for eye 
dominance can be used. 
1. Ocular Preference Determination Methods  
Method 1:   Determine which eye is the â€œsighting eye.â€ Have the patient point to an object at 
the far end of the room. Cover one eye. If the patient is still pointing directly at 
the object, the eye being used is the dominant (sighting) eye. 
Method 2: Determine which eye will accept the added power with the least reduction in 
vision. Place a hand-held trial lens equal to the spectacle near ADD in front of one eye and then the other while the distance refractive error correction is in 
place for both eyes. Determine whether the patient functions best with the near 
ADD lens over the right or left eye. 
Other methods include the â€œRefractive Error Methodâ€ and the â€œVisual Demands Method.â€ 
2. Refractive Error Method 
For anisometropic correction, it is generally best to fit the more hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near. 
3. Visual Demands Method 
Consider the patientâ€™s occupation during the eye selection process to determine the critical 
vision requirements. If a patientâ€™s gaze for near tasks is usually in one direction, correct the eye 
on that side for near. 
Example: 
A secretary who places copy to the left side of the desk will function best with the near lens on 
the left eye. 
C. Special Fitting Characteristics 
1. Unilateral Vision Correction Requirement 
There are circumstances where only one contact [CONTACT_35571]. As an example, an emmetropic 
patient would only require a near lens, whereas a bilateral myope would require corrective lenses on both eyes. 
  
CR-5913 v2.0, Amendment 1.0 Page 80 of 183 JJVC CONFIDENTIAL
22 
 Examples: 
A presby[CONTACT_35572] a +1.75D ADD would have a +1.75D lens on the 
near eye and the other eye left without correction. 
A presby[CONTACT_35573] a +1.50D ADD who is â€“2.50D myopic in the right eye and â€“1.50D 
myopic in the left eye may have the right eye corrected for distance and the left eye uncorrected 
for near. 
2. Near ADD Determination 
Always prescribe the lens power for the near eye that provides optimal near acuity at the 
midpoint of the patientâ€™s habitual reading distance. However, when more than one power 
provides optimal reading performance, prescribe the least plus (most minus) of the powers.  
3. Trial Lens Fitting 
A trial fitting is performed in the office to allow the patient to experience monovision correction. 
Lenses are fit according to the GENERAL FITTING GUIDELINES for base curve selection described 
in this guide. 
Case history and standard clinical evaluation procedure should be used to determine the 
prognosis. Determine the distance correction and the near correction. Next determine the near ADD. With trial lenses of the proper power in place, observe the reaction to this mode of 
correction. 
Allow the lenses to settle for about [ADDRESS_816285] the patient look at you. Assess the patientâ€™s reaction to distance vision under these circumstances. Then have the pa tient look at familiar near objects such as a 
watch face or fingernails. Again assess the reaction. As the patient continues to look around the room at both near and distance objects, observe the reactions. Only after these vision tests are completed should the patient be asked to read print. Evaluate the patientâ€™s reaction to large print (e.g., typewritten copy) at first and then graduate to news print and finally smaller type sizes. 
After the patientâ€™s performance under the above conditions is completed, tests of visual acuity 
and reading ability under conditions of moderately  dim illumination should be attempted.  
An initial unfavorable response in  the office, while indicative of a guarded prognosis, should not 
immediately rule out a more extensive trial under the usual conditions in which a patient 
functions.  
   
CR-[ADDRESS_816286] several weeks of wear (when adaptation is occurring), it may be advisable for the patient to only drive during optimal driving 
conditions. After adaptation and success with these activities, the patient should be able to drive 
under other conditions with caution.  
5. Other Suggestions 
The success of the monovision technique may be further improved by [CONTACT_253457]: 
Âƒ Have a third contact [CONTACT_13293] (distance power) to use when critical distance viewing is needed. 
Âƒ Have a third contact [CONTACT_13293] (near power) to use when critical near viewing is needed. 
Âƒ Have supplemental spectacles to wear over the monovision contact [CONTACT_615594]. This is particularly applicable for 
those patients who cannot meet their state driverâ€™s license requirements with a monovision 
correction. 
Âƒ Make use of proper illumination when carrying out visual tasks. 
Monovision fitting success can be improved by [CONTACT_615595]: 
Âƒ Reverse the distance and near eyes if a patient is having trouble adapting. 
Âƒ Refine the lens powers if there is trouble with adaptation. Accurate lens power is critical for 
presby[CONTACT_35577]. 
Âƒ Emphasize the benefits of clear near vision, and straight ahead and upward gaze with 
monovision. 
  
CR-[ADDRESS_816287] appropriately left to the Eye Care 
Professional in conjunction with the patient af ter carefully considering the patientâ€™s needs. 
All patients should be supplied with a copy of  the PATIENT INSTRUCTION GUIDE for these lenses. 
Copi[INVESTIGATOR_35461].acuvue.com. 
PATIENT MANAGEMENT 
Dispensing Visit 
Each sterile lens is supplied in a foil-sealed plastic package containing buffered saline solution with 
povidone. To remove the lens from the container, peel back the foil seal, place a finger on the lens, and 
slide the lens up the side of the bowl of the lens package until it is free of the container.  
Âƒ Evaluate the physical fit and visual acuity of the lens on each eye.  
Âƒ Teach the patient how to apply and remove his or her lenses.  
Âƒ Explain daily disposable lens wear and schedule a follow-up examination.  
Âƒ Provide the patient with a copy of the PA TIENT INSTRUCTION GUIDE for these lenses.  
Copi[INVESTIGATOR_35461].acuvue.com. 
REVIEW THESE INSTRUCTIONS WITH THE PATIENT SO THAT HE OR SHE CLEARLY 
UNDERSTANDS THE PRESCRIBED WEARING AND REPLACEMENT SCHEDULES. 
Follow-Up Examinations 
Follow-up care (necessary to ensure continued successful contact [CONTACT_13279]) should include routine 
periodic progress examinations, management of specific problems, if any, and a review with the patient 
of the wear schedule, daily disposable moda lity, and proper lens handling procedures. 
A. Recommended Follow-up Examination Schedule (complications and specific problems 
should be managed on an individual patient basis): 
1. One week from the initial lens dispensing to patient 
2. One month post-dispensing 
3. Every three to six months thereafter 
NOTE:  Preferably, at the follow-up visits, lenses should be worn for at least six hours.  
 
  
CR-5913 v2.0, Amendment 1.0 Page 83 of 183 JJVC CONFIDENTIAL
25 
 B. Recommended Procedures for Follow-Up Visits: 
1. Solicit and record patientâ€™s symptoms, if any. 
2. Measure visual acuity monocularly and binocularly at distance and near with the 
contact [CONTACT_13276].  
3. Perform an over-refraction at distance and near to check for residual refractive 
error. 
4. With the biomicroscope, judge the lens fitting characteristics (as described in 
the GENERAL FITTING GUIDELINES ) and evaluate the lens surface for deposits 
and damage. 
5. Following lens removal, examine the cornea and conjunctiva with the biomicroscope and fluorescein (unless contraindicated).  
Âƒ The presence of vertical corneal striae in the posterior central cornea and/or corneal neovascularization is indicative of excessive corneal edema. 
Âƒ The presence of corneal staining and/or limbal-conjunctival hyperemia can be indicative of an unclean lens, a reaction to solution preservatives, excessive lens wear and/or a poorly fitting lens. 
Âƒ Papi[INVESTIGATOR_615555]/or damaged lens.  
6. Periodically perform keratometry and spectacle refractions. The values should 
be recorded and compared to the baseline measurements. 
If any observations are abnormal, use professional judgment to alleviate the problem and restore the 
eye to optimal conditions. If the criteria for successful fit are not satisfied during any follow-up 
examinations, repeat the patientâ€™s trial fitting procedure and refit the patient. 
WEARING SCHEDULE 
The wearing schedule should be determined by [CONTACT_35578].  Regular checkups, as 
determined by [CONTACT_35578], are also extremely important.  
Patients tend to over wear the lenses initially. The Eye Care Professional should emphasize the 
importance of adhering to the initial maximum we aring schedule.  Maximum wearing time should be 
determined by [CONTACT_35579]â€™s physiological eye condition, because individual response to contact [CONTACT_35580].  
  
CR-5913 v2.0, Amendment 1.0 Page 84 of 183 JJVC CONFIDENTIAL
26 
 The maximum suggested wearing time for these lenses is: 
Day Hours 
[ADDRESS_816288] lenses. 
x Do not use saliva or anything other than the recommended solutions for lubricating or rewetting 
lenses. Do not put lenses in the mouth. 
x Eye Care Professionals may recommend a lubricating/rewetting solution which can be used to 
wet (lubricate) lenses while they are bein g worn to make them more comfortable. 
Care for a Sticking (Non-Moving) Lens 
If the lens sticks (stops moving), the patient should be instructed to apply a few drops of the 
recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to move freely on the eye before removing it. If non-movement of the lens continues after a few minutes, 
the patient should  immediately  consult the Eye Care Professional.
 
EMERGENCIES 
The patient should be informed that  if chemicals of any kind (household products, gardening solutions, 
laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY 
WITH TAP WATER AND IMMEDIATELY CONTACT [CONTACT_35581] A HOSPI[INVESTIGATOR_35466].
 
HOW SUPPLIED 
Each sterile lens is supplied in a foil-sealed plastic package containing buffered saline solution with 
povidone. The plastic package is marked with the following: 
x 1-DAY ACUVUEÂ® MOISTÂ®:    base curve, power, diameter, lot number, and expi[INVESTIGATOR_320] 
x 1-DAY ACUVUEÂ® MOISTÂ® for ASTIGMATISM:    base curve, power, diameter, cylinder, axis, lot 
number, and expi[INVESTIGATOR_320] 
x 1-DAY ACUVUEÂ® MOISTÂ® MULTIFOCAL:     base curve, power, diameter, ADD, lot number, and 
expi[INVESTIGATOR_615556]-5913 v2.0, Amendment 1.0 Page 86 of 183 JJVC CONFIDENTIAL
 
 REPORTING OF ADVERSE REACTIONS 
All serious adverse experiences and adverse reactions observed in patients wearing these lenses or 
experienced with these lenses should be reported to: 
 
 
  
 
  
 
 
[COMPANY_012] Vision Care, Inc. 
[ADDRESS_816289] 
Jacksonville, FL [ZIP_CODE] 
[LOCATION_003] 
Tel: [PHONE_564] 
www.acuvue.com  
 
 
  
 
   
   
 
 
Â©[COMPANY_012] Vision Care Companies 2015 
Printed in [LOCATION_003] 
Revision date: 09/14 
 Revision number: M-09-14-00 
  
1-DAY ACUVUEÂ® MOISTÂ® and LACREONÂ® are Trademarks of [COMPANY_012] Vision Care Companies 
CR-5913 v2.0, Amendment 1.0 Page 87 of 183 JJVC CONFIDENTIAL
9&7 $33(1',;'&/,1,&$/ 7(&+1,&$/ 352&('85(6 &73
x  LIMBAL & CONJUNCTIVAL (BULBAR) REDNESS 
x  EXPANDED SODIUM FLUORESCEIN CORNEAL STAINING 
x  DETERMINATION OF NEAR ADD 
x   LENS FITTING CHARACTERISTICS
x  SUBJECT REPORTED OCULAR SYMPTOMS 
x  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS 
x  BIOMICROSCOPY SCALE 
x  DISTANCE AND NEAR VISUAL ACUITY EVALUATION 
x  TORIC FIT EVALUATION 
CR-5913 v2.0, Amendment 1.0 Page 88 of 183 JJVC CONFIDENTIAL
9&7 $33(1',; ( 35(6%<23,& 6<037206
3UHVE\RSLF 6\PSWRPV 4XHVWLRQQDLUH
1. Do you notice that you often have to hold things farther away  so that you could read 
them?
2. Do you notice that you often have difficulty focusing on near  objects (i.e., 
experiencing blurry vision when looking at things close-up)? 
3. Do you often have headaches or  eyestrains, or feel fatigued, when read or conduct 
other near activities?
4. Do you often have difficulty reading small or fine prints, su ch as phone books, 
medicine bottles or package labels, etc.?
5. Do you often have difficulty reading under dim or low light? 
CR-5913 v2.0, Amendment 1.0 Page 89 of 183 JJVC CONFIDENTIAL
9&7 $33(1',;* ),77,1* *8,'( 237,21
CR-5913 v2.0, Amendment 1.0 Page 91 of 183 JJVC CONFIDENTIAL
9&7 $33(1',;+ ),77,1* *8,'( 237,21
CR-5913 v2.0, Amendment 1.0 Page 96 of 183 JJVC CONFIDENTIAL
9&7 $33(1',;,68%-(&7 352'8&7 &21&(37
CR-5913 v2.0, Amendment 1.0 Page 103 of 183 JJVC CONFIDENTIAL
9&7 $33(1',; - (&3,17(59,(: ',6&866,210$7(5,$/6
CR-5913 v2.0, Amendment 1.0 Page 105 of 183 JJVC CONFIDENTIAL
9&7 /,0%$/ 	 &21-81&7,9$/ %8/%$55('1(66
CR-5913 v2.0, Amendment 1.0 Page 131 of 183 JJVC CONFIDENTIAL
9&7 (;3$1'('62',80)/825(6&(,1&251($/ 67$,1,1*
CR-5913 v2.0, Amendment 1.0 Page 139 of 183 JJVC CONFIDENTIAL
9&7 '(7(5
0,1$7,212)1($5$''
CR-5913 v2.0, Amendment 1.0 Page 144 of 183 JJVC CONFIDENTIAL
9&7 /(16 ),77,1*&+$5$&7(5,67,&6
CR-5913 v2.0, Amendment 1.0 Page 152 of 183 JJVC CONFIDENTIAL
9&7 68%-(&7 5(3257('2&8/$5 6<037206
CR-5913 v2.0, Amendment 1.0 Page 159 of 183 JJVC CONFIDENTIAL
9&7 '(7(50,1$7,212)',67$1&( 63+(52&</,1'5,&$/
5()5$&7,216
CR-5913 v2.0, Amendment 1.0 Page 161 of 183 JJVC CONFIDENTIAL
9&7 %,20,&526&23<6&$/(
CR-5913 v2.0, Amendment 1.0 Page 168 of 183 JJVC CONFIDENTIAL
9&7 ',67$1&( $1'1($59,68$/ $&8,7<(9$/8$7,21
CR-5913 v2.0, Amendment 1.0 Page 174 of 183 JJVC CONFIDENTIAL
9&7 725,& ),7 (9$/8$7,21
CR-5913 v2.0, Amendment 1.0 Page 179 of 183 JJVC CONFIDENTIAL
9&7 [ZIP_CODE]&2/ &203/,$1&( ,19(67,*$72566,*1$785( 3$*(
Protocol Number and T itle: CR-[ADDRESS_816290] Lens Fitting Guide    
Version and Date: v2.0, Amendment 1.[ADDRESS_816291] this study according to GCP and ICH guidelin es, the Declaration of 
Helsinki, ISO [ZIP_CODE], [LOCATION_002] (US) Code of Federal Regulat ions (CFR), and the 
pertinent individual country law s/regulations and to comply wit h its obligations, subject to 
ethical and safety considerations . The Principal Investigator i s responsible for ensuring that 
all clinical site pers onnel, including Sub-I nvestigators adhere to all ICH regulations and GCP 
guidelines regarding clinical trials during and after study com pletion.
I will assure that no deviation fro m, or changes to the protocol will take place without prior 
agreement from the Sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard( s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including Sub-Investigators 
adhere to all ICH regulations a nd GCP guidelines regarding clin ical trials during and after 
study completion. 
All clinical site personnel invol ved in the conduct of this stu dy have completed Human 
Subjects Protection Training.  I agree to ensure that all c linical site personnel involved in the conduct of this study are 
informed about their obligations in meeting the above commitmen ts.
I shall not disclose the infor mation contained in this protocol  or any results obtained from 
this study without w ritten authorization.
Principal 
Investigator:
[INVESTIGATOR_19540] (Printed)
Institution/Site:
Institution/Site Name
[CONTACT_16277]/Site Address
CR-5913 v2.0, Amendment 1.0 Page 183 of 183 JJVC CONFIDENTIAL